

**Curriculum Vitae****Dr. Anne W. M. LEE****Medical Professional Qualifications & Education**

	<u>Year</u>
<u>Primary Degree</u>	
MB BS (HK)	1976
<u>Postgraduate Degrees</u>	
FRCR (UK)	1983
FHKCR (HK)	1992
FHKAM (HK)	1993
MD (HK)	2008
<u>Degree-Granting Education</u>	
Medical Faculty, The University of Hong Kong	1971-1976
<u>Postgraduate Training in Overseas Centers</u>	
Royal Marsden Hospital, U. K.	1981-1982
Stanford University, U. S. A.	1988
Princess Margaret Hospital, Canada	1988

**Academic Appointments**

<u>The University of Hong Kong</u>	
Department of Clinical Oncology, Li Ka Shing Faculty of Medicine	
Honorary Clinical Associate Professor	2000-2009
Honorary Clinical Professor	2009-2015
Clinical Professor and Head	since 2015
Alice Ho Miu Ling Nethersole Charity Foundation Professorship in Holistic Cancer Care	Since 2017
<u>The Chinese University of Hong Kong</u>	
Department of Clinical Oncology, Faculty of Medicine	
Adjunct Associate Professor	1999-2005
<u>Hong Kong Polytechnic University</u>	
Expert Adviser for Research Committee	1995
Member of Advisory Committee on Radiography	1998
<u>Peking Union Medical College Hospital</u>	
Honorary Professor	since 2016

**Clinical and Administrative Appointments**

<b><u>Institute of Radiology and Oncology, Queen Elizabeth Hospital, Hong Kong</u></b>	
Medical & Health Officer	1977-1985
Senior Medical & Health Officer	1985-1991
Consultant	1991-1993
<b><u>Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong</u></b>	
Consultant (full-time)	1993-2012
Chief of Service	1994-2012
Consultant (Part-time)	2012
Consultant (Honorary)	2012-2018
<b><u>Hospital Authority Hong Kong East Cluster</u></b>	
Coordinator of Clinical Oncology	2001-2005
Cluster Chief of Service of Clinical Oncology	2005-2011
Consultant (Healthcare management) for Training Center (Honorary)	2013-2018
<b><u>The University of Hong Kong - Shenzhen Hospital</u></b>	
Chief of Service, Center of Clinical Oncology	since 2012
Clinical Service Coordinator (Quality and Safety)	since 2014
Deputy Hospital Chief Executive (Clinical Service)	since 2017
<b><u>Gleneagles Hong Kong Hospital</u></b>	
Chair of Specialty for Oncology	2015-2018
<b><u>Department of Clinical Oncology, Queen Mary Hospital, Hong Kong</u></b>	
Consultant (Honorary)	since 2015
Deputy Chief of Service of Clinical Oncology	since 2017

**Experience as Examiners / Assessors**

<b><u>Fellowship Examinations for clinical oncologists</u></b>	
Conjoint Fellowship Examination (Part II) by Royal College of Radiologists (UK) and Hong Kong College of Radiologists	1995, 1996, 1998, 1999
Exit examination by Hong Kong College of Radiologists	2000, 2003, 2011, 2015
<b><u>Hong Kong Polytechnic University</u></b>	
External examiner for Bachelor Degree in Radiography	1992-1998
External assessor for conferment of title of professor	1998

**Other Professional Qualifications**

<b><u>Traditional Chinese Medicine</u></b>	
Certificate in Chinese Medicine for Hospital Authority Medical and Healthcare Professionals (by The University of Hong Kong)	2011
<b><u>International Standard Organization (ISO) Quality Management System</u></b>	
ISO 9001: 2000 Auditor/Lead Auditor Certificate (by BSI)	2001
QMS 2000 Auditor (by IRCA)	2007-2009
QMS 2008 Auditor (by IRCA)	2009-2012

**Awards & Honors**

Outstanding Team Award by Hospital Authority	
Leader of Quality Management Team	2003
Member of Committee on Public Private Interface	2004
Sir Patrick Manson Gold Medal by The University Hong Kong	2008
Gilbert H. Fletcher Distinguished Professor Lecturer	2009
by The University of Texas, M.D. Anderson Cancer Center, U.S.A.	
Honorary Membership	2012
by European Society of Therapeutic Radiology and Oncology	
Honorary Membership	2013
by Radiological Society of North America	
Wharton Lecturer	2015
by The University of Toronto, Princess Margaret Hospital, Canada	
深圳市巾帼文明岗	2015
深圳市妇联授予	
深圳好医生	2018
深圳市卫生和计划生育委员会授予	
福建省科學技術獎一等獎 – 項目「基於MRI的鼻咽癌臨床分期和精確放療的應用研究」	2018
福建省人民政府授予	
Honorary Fellow	2019
by American College of Radiology	

**Hospital Governance & Leading Role in Hospital Services Committee**

Bradbury Hospice	
Member of Hospital Governing Committee	1995-2005
Nam Long Hospital	
Honorary Consultant (Clinical Oncology)	1998-1999
Member of Hospital Governing Committee	2002-2004
Hong Kong Hospital Authority	
Specialist Coordinator for e-Knowledge Gateway	2000-2011
Member of Hospital Authority Research Ethics Committee	2005-2007
Member of Drug Advisory Committee	2008-2012
Chairman of Coordinating Committee (Clinical Oncology)	2010-2012
External Advisor, Li Ka Shing Foundation “Heart of Gold” Hospice Service Program – Project Management Committee	since 2014
Hong Kong East Cluster	
Chairman of Hospital Ethics Committee of Pamela Youde Nethersole Eastern Hospital	2000-2003
Deputy Chairman of Ethics Committee of Hong Kong East Cluster	2003-2007
Chairman of Cancer Services Coordinating Committee	2005-2012

Chairman of Community Service Committee (Cancer)	2006-2012
Hong Kong Anti-Cancer Society Jockey Club Cancer Rehabilitation Center	
Vice Chairman of Hospital Governing Committee	2008-2010
Chairman of Clinical Research Ethics Committee	2008-2010
St. Paul's Hospital	
Member of Radiology Advisory Committee	2011-2013

### **Appointments by the Hong Kong Special Administrative Region**

Member of Government's Cancer Coordinating Committee	2001-2012
Member of Radiation Board	2005-2011
Member of Radiological Protection Advisory Group	2007-2013
Panel of Assessors for Hong Kong Medical Council	2011-2012
Member of Public Affairs Forum	2011

### **Non-Government Community Services**

#### **Local**

Hong Kong Anti-Cancer Society	
Member of Executive Council	since 1994
Chairman of Cancer Education Subcommittee	1994-2003
Member of Cancer Education Subcommittee	2004-2010
Chairman of Cancer Research Subcommittee	2004-2012
Vice-Chairman	since 2008
Chairman of Cancer Education, Prevention and Early Detection Committee	since 2015
Hong Kong Council on Smoking and Health	
Co-opted member of Legislative Committee	2017-2020

#### **Overseas**

Associaçao Dos Amigos Da Caridade de Macau	
Honorary Consultant	1996-2002

### **Expert Member / Coordinator for International Professional Organizations**

American Society of Therapeutic Radiology and Oncology	
Consultant to the International Relations Committee	2000-2007
ASTRO Leadership Team	2001
Union of International Cancer Control	
UICC TNM Expert Advisory Panel on Head and Neck Cancers	since 2001
Coordinator of UICC TNM Global Advisory Group	since 2013
UICC Board of Directors	since 2016
International Agency for Research on Cancer	
Expert Member for WHO Classification of Head and Neck Tumours	2003
European Society of Medical Oncology	
Faculty Member on Nasopharyngeal Cancer	2006
American Joint Committee on Cancer	

Expert Panel on Head and Neck Cancers	since 2014
Chairman of Subcommittee on Nasopharyngeal Cancer	
Expert Panel on Skin Cancers	since 2014
International Atomic Energy Agency	
Coordinator for Technical Meeting on “Genetic Characteristics and Radiotherapy Response of Nasopharyngeal Carcinoma”	2014
EORTC Protocol Review Committee (PRC)	
External reviewer	2017
European Society for Radiotherapy & Oncology	
APAC Advisory Board Member	since 2017
International Head and Neck Scientific Group	
Member	since 2018

### **Leading Role in Local / National Professional Organizations**

#### **National**

Pan-Pearl River Delta Radiation Oncology Conference Committee	
Committee Member	since 2006
Macau Oncology Association	
Honorary Consultant	2006
National Cancer Staging Committee of China	
Co-Chairman of National Preparatory Committee	2010-2013
Chairman of Hong Kong Regional TNM Cancer Staging Subcommittee	since 2010
Vice Chairman of National Committee	since 2013

#### **Local**

Hong Kong College of Radiologists	
Secretary of the Membership Committee	1991-1994
Member of the Scientific and Education Committee	1992-1994
Member of the Subcommittee on Continuous Medical Education	1994-1996
Council member	since 2008
Vice President	since 2009
Hong Kong Head and Neck Society (Limited)	
Treasurer	1992-1994
President Elect	1995
President	1996
President Elect	2002
President	2003
Hong Kong Nasopharyngeal Cancer Study Group (Limited)	
Founding Vice Chairman	1999-2004
Chairman	2005-2007
Council member	2007-2011
Chairman	Since 2018
Hong Kong Academy of Medicine	
Faculty Member on Treatment of Tobacco Dependence	2010

Hong Kong Society of Clinical Oncology Council member	since 1991
Ho Hung Chiu Medical Education Foundation Limited Council Member	since 1997

### **Editor for Professional Journals**

#### **International Journals**

Oral Oncology Associate Editor for Translational Research	since 2011
American Journal of Clinical Oncology Board of Editors	1997
International Journal of Radiation Oncology, Biology and Physics Board of Editors	1998-2000
Radiotherapy & Oncology Board of Editors	since 2010
Clinical Oncology Board of Editors	since 2011
Journal of Clinical Oncology Board of Editors	since 2013
Journal of International Journal of Head and Neck Science Board of Editors	since 2016
Acibadem Health Sciences Journal International Advisory Board Member	since 2017

#### **National Journals**

Chinese Clinical Oncology Board of Editors	since 2016
-----------------------------------------------	------------

#### **Local Journals**

The Hong Kong Radiographers Journal Honorary Editorial Advisor	since 1997
The Journal of the Hong Kong College of Radiologists Board of Editors	1998-2000

### **Leading Role in coordinating large-scale research projects**

Hong Kong Nasopharyngeal Cancer Study Group Leading multi-center randomized clinical trials and retrospective studies.	since 1999
Area of Excellence Scheme – Center for Nasopharyngeal Cancer Research Leader of Research Committee on Clinical Sciences	2009-2018
Member of Executive Management Committee	2009-2018

Prospective Randomized Study on Therapeutic Gain Achieved by Addition of Chemotherapy for T1-4N2-3M0 Nasopharyngeal Carcinoma (NPC-9901 Trial) Principal Investigator	1999
Prospective Randomized Study on Therapeutic Gain Achieved by Chemoradiation and/or Accelerated Radiation for T3-4N0-1M0 Nasopharyngeal Carcinoma (NPC-9902 Trial) Principal Investigator	1999
Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) versus Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer Asian Representative in Trial Management Committee	2005
Randomized Trial comparing the Therapeutic Gain by Induction-Concurrent Chemoradiation vs. Concurrent-Adjuvant Chemoradiation and the Efficacy of Capecitabine vs. 5-Fluorouracil for Advanced Nasopharyngeal Carcinoma (NPC-0501 Trial) Principal Investigator	2006
Meta-Analysis of Chemotherapy in Naso-Pharynx Carcinoma Steering Committee – Clinical Coordinator	2011
A Situation Analysis of National Radiotherapy resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes - Coordinated Research Project (CRP) (325-E3-TM-47712) by the International Atomic Energy Agency Principal Investigator	2016
Prognostic and predictive tissue biomarkers in locally advanced nasopharyngeal carcinoma treated with radiotherapy alone or in conjunction with chemoradiotherapy: pooled analysis of data from the NPC-9901, NPC-9902 and NPC-0501 studies Principal Investigator	2016

### **Records in Research Grants / Project Funding**

#### **Area of Excellence Scheme – Center for Nasopharyngeal Cancer Research Projects**

University Grants Committee (as a Co-PI 2009-2018)	HK\$	1,880,000
Health and Health Service Research Fund	HK\$	1,200,000

#### **Hong Kong Nasopharyngeal Cancer Study Group – Clinical Trials**

Hong Kong Hospital Authority	HK\$	1,000,000
Hong Kong Anti-Cancer Society	HK\$	650,000
Hong Kong Nasopharyngeal Cancer Study Group	HK\$	600,000
Ho Hung Chiu Medical Foundation Limited	HK\$	324,180
Hong Kong Cancer Fund	HK\$	317,040

#### **深圳市科技计划 (Shenzhen Science and Technology Project)**

肿瘤临床路径的规划及其应用与管理之研发 (Research on design, application and monitoring of clinical pathway) Principal Investigator	RMB	100,000
		2014

#### **International Atomic Energy Agency**

A Situation Analysis of National Radiotherapy resources and Patterns of Care	Euro	473,000
------------------------------------------------------------------------------	------	---------

for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes.

Principal Investigator 2016

University Research Committee - Seed Funding for Basic Research

Prognostic and predictive tissue biomarkers in locally advanced nasopharyngeal carcinoma treated with radiotherapy alone or in conjunction with chemoradiotherapy: pooled analysis of data from the NPC-9901, NPC-9902 and NPC-0501 studies. HK\$ 300,000

Principal Investigator 2016

Shenzhen Sanming project

RMB 12,000,000  
2017-2021

**MD Thesis**

Therapeutic Benefits of Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Carcinoma, The University of Hong Kong, 2008



## Publications

### Book

1. Lu JJ, Cooper JS, **Lee AWM** (Eds). Nasopharyngeal Cancer. Medical Radiology - Radiation Oncology. Verlag Berlin Heidelberg: Springer, 2010.
2. Brierley JD, Gospodarowicz MK, Wittekind C, O'Sullivan B, Manson M, Asamura H, **Lee A**, Eycken EV, Denny L, Amin MB, Gupta S (Eds). TNM Classification of MALIGNANT TUMOURS. 8<sup>th</sup> Edition. WILEY Blackwell, 2017.
3. **Lee AWM**, Lung ML, Ng WT (Eds). Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. 1st Edition. Elsevier, 2019.

### Chapters

1. **Lee AWM**.\* Complications of radiation therapy. In: Nasopharyngeal Carcinoma. CA Van Hasselt, A Gibb (Eds), 1<sup>st</sup> edition. Hong Kong: Chinese University Press, pp 221-234, 1991.
2. **Lee AWM**.\* Yau TK. Complications of radiation therapy. In: Nasopharyngeal Carcinoma. VFH Chong, SY Tsao (Eds). Singapore: Armour Publishing Pte Ltd, pp 114-127, 1997.
3. **Lee AWM**.\* Complications of radiation therapy. In: Nasopharyngeal Carcinoma. CA Van Hasselt, A Gibb (Eds), 2<sup>nd</sup> edition. Hong Kong: Chinese University Press, pp 255-276, 1999.
4. O'Sullivan B, Irish J, Siu L, **Lee AWM**. Head and neck cancer. In: Manual of Clinical Oncology. RE Pollock (Ed), 7<sup>th</sup> edition. International Union against Cancer. New York: Wiley-Liss, Inc., pp 341-358, 1999.
5. Chan JKC, Bray F, McCarron P, Foo W, **Lee AWM**, Yip T, Kuo TT. Nasopharyngeal carcinoma. In: Pathology & Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours, Lyon: IARC Press, pp 85-97, 2005.
6. **Lee AWM**.\* Perez CA, Law CK, Chua D, Wei W, Chong VFH. Nasopharynx. In: Principles and Practice of Radiation Oncology. EC Halperin, C Perez, LW Brady (Eds), 5<sup>th</sup> edition. Philadelphia: Lippincott Williams & Wilkins, pp 820-857, 2008.
7. **Lee AWM**.\* Yeung MWR, Ng WT. Nasopharynx. In: Functional Preservation and Quality of Life in Head and Neck Radiotherapy PM Harari, NP Connor, C Grau. (Eds). Verlag Berlin Heidelberg: Springer, pp 57-73, 2009.
8. **Lee AWM**.\* Neoadjuvant chemotherapy: Trials and conclusions. In Nasopharyngeal Cancer. Medical Radiology - Radiation Oncology, Lu JJ, Cooper JS, **Lee AWM** (Eds). Verlag Berlin Heidelberg: Springer, pp 183-192, 2010.
9. **Lee AWM**.\* Ng WT, Yau TK, Law SCK, Wei WI. Management of the nasopharyngeal carcinomas. In: Head and Neck Cancer: Multimodality Management. 1<sup>st</sup> edition. J. Bernier (Ed). Springer, pp 381-400, 2011.
10. Sze HCK, Lam KO, **Lee AWM**. Early stage nasopharyngeal carcinoma. In: Nasopharyngeal Carcinoma: Management Strategies. S Yom, J Wee (Eds). Future Medicine Ltd, London, pp 55-74, 2014.
11. Ng WT, Ngan RKC, Chan OSH, Sze HCK, Chan JYW, **Lee AWM**. Management of

- nasopharyngeal carcinoma. In: Head and Neck Cancer: Multimodality Management. 2<sup>nd</sup> edition. J. Bernier (Ed). Springer, pp 381-400, 2015.
12. **Lee AWM,\*** Ng WT, Le QT, Chan ATC, Chan JYW, Sze HCK. Nasopharynx. In: The UICC Manual of Clinical Oncology. 9<sup>th</sup> edition. O'Sullivan B (ed). Wiley Blackwell, pp 512-523, 2015.
  13. Lee VHF, Chang ATY, Ng WT and **Lee AWM**. Evidenced-Based Management of Nasopharyngeal Cancers in the Modern Era. Chemoradiotherapy: Concurrent Uses, Efficacy and Impact on Prognosis, 2017.
  14. **Lee AWM**, Lydiatt WM, Colevas D, Glastonbury CM, Le QTX, O'Sullivan B, Weber RS and Shah JP. Nasopharynx. In: AJCC Cancer Staging Manual. 8<sup>th</sup> Edition. Springer, pp103-111, 2017.
  15. **Lee AWM**, Zong JF, Pan JJ, Choi HCW, Sze HCK. Staging of Nasopharyngeal Carcinoma based on 8th Edition of the AJCC/UICC Staging System. In: Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. 1st Edition. Lee AWM, Lung ML, Ng WT (Eds). Elsevier, Chapter 9, pp 179-203, 2019.
  16. Lee VHF, Lam KO, **Lee AWM**. Standard of Care for Nasopharyngeal Carcinoma (2018-2020). In: Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. 1st Edition. Lee AWM, Lung ML, Ng WT (Eds). Elsevier, Chapter 10, pp 205-238, 2019.

**Articles in Peer-reviewed Journals**

1. Lam KSL, Ho JHC, **Lee AWM**, Tse VKC, Chan PK, Wang C, Ma JTC, Yeung RTT. Symptomatic Hypothalamic-Pituitary Dysfunction in Nasopharyngeal Carcinoma Patients following Radiation-Therapy - A Retrospective Study. *Int J Radiat Oncol Biol Phys*, 13(9):1343-1350, 1987
2. **Lee AWM**,\* Ng SH, Ho JHC, Tse VKC, Poon YF, Tse CCH, Au GKH, Lau WH, Foo WWL. Clinical Diagnosis of Late Temporal-Lobe Necrosis following Radiation-Therapy for Nasopharyngeal Carcinoma. *Cancer*, 61(8):1535-1542, 1988
3. **Lee AWM**,\* Sham JST, Poon YF, Ho, JHC. Treatment of Stage-I Nasopharyngeal Carcinoma - Analysis of the Patterns of Relapse and the Results of Withholding Elective Neck Irradiation. *Int J Radiat Oncol Biol Phys*, 17(6):1183-1190, 1989
4. **Lee AWM**,\* Cheng LOC, Ng SH, Tse VKC, Au GKH, O SK, Poon YF. Magnetic-Resonance-Imaging in the Clinical- Diagnosis of Late Temporal-Lobe Necrosis following Radiotherapy for Nasopharyngeal Carcinoma. *Clin Oncol*, 42(1):24-31, 1990
5. **Lee AWM**,\* Poon YF, Foo W, Law SCK, Cheung FK, Chan DKK, Tung SY, Thaw M, Ho JHC. Retrospective Analysis of 5037 Patients with Nasopharyngeal Carcinoma Treated during 1976-1985 - Overall Survival and Patterns of Failure. *Int J Radiat Oncol Biol Phys*, 23(2):261-270, 1992
6. **Lee AWM**,\* Law SCK, Ng SH, Chan DKK, Poon YF, Foo W, Tung SY, Cheung FK, Ho JHC. Retrospective Analysis of Nasopharyngeal Carcinoma Treated during 1976-1985 - Late Complications following Megavoltage Irradiation. *Brit J Radiol*, 65(778):918-928, 1992
7. **Lee AWM**. Decision-Making for Reirradiation of Nasopharyngeal Carcinoma - Response. *Int J Radiat Oncol Biol Phys*, 26(5):907-907, 1993
8. **Lee AWM**,\* Ng SH, Tse VKC, Chiu HM, Thaw M. Bilateral Temporal Lobectomy for Necrosis Induced by Radiotherapy for Nasopharyngeal Carcinoma. *Acta Oncologica*, 32(3):343-345, 1993
9. **Lee AWM**,\* Law SCK, Foo W, Poon YF, Chan DKK, O SK, Tung SY, Cheung FK, Thaw M, Ho JHC. Nasopharyngeal Carcinoma - Local-Control by Megavoltage Irradiation. *Brit J Radiol*, 66(786):528-536, 1993
10. **Lee AWM**,\* Law SCK, Foo W, Poon YF, Cheung FK, Chan DKK, Tung SY, Thaw M, Ho JHC. Retrospective Analysis of Patients with Nasopharyngeal Carcinoma Treated during 1976-1985 - Survival After Local Recurrence. *Int J Radiat Oncol Biol Phys*, 26(5):773-782, 1993
11. Leung TW, **Lee AWM**, Chan DKK. Definitive Radiotherapy for Carcinoma of the Oral Tongue. *Acta Oncologica*, 32(5):559-564, 1993
12. Yau TK, Yiu HY, **Lee AWM**. Case Report: Central Pontine Myelinolysis after Cisplatin-Containing Chemotherapy for Nasopharyngeal Carcinoma. *Clin Oncol*, 5(6):395-396, 1993
13. Chan JKC, Tsang WYW, Ng CS, Tang SK, Yu HC, **Lee AWM**. Follicular Dendritic Cell Tumors of the Oral Cavity. *Am J Surg Path*, 18(2):148-157, 1994
14. Tsang WYW, Chan JKC, Loo KT, Wong KF, **Lee AWM**. Granulomatous Slack Skin. *Histopath*, 25(1):49-55, 1994

15. **Lee AWM,\*** Chan DKK, Fowler JF, Poon YF, Law SCK, Foo W, Tung SY, Cheung FK, Ho JHC, Chappell R. T-1 Nasopharyngeal Carcinoma – The Effect of Waiting Time on Tumor Control. *Int J Radiat Oncol Biol Phys*, 30(5):1111-1117, 1994
16. Wong KF, Chan JKC, Li LPK, Yau TK, **Lee AWM**. Primary Cutaneous Plasmacytoma: Report of Two Cases and Review of the Literature. *Am J Dermatopath*, 16(4):392-397, 1994
17. **Lee AWM,\*** Chan DKK, Fowler JF, Poon YF, Foo W, Law SCK, O SK, Tung SY, Chappell R. Effect of Time, Dose and Fractionation on Local Control of Nasopharyngeal Carcinoma. *Radiother Oncol*, 36(1):24-31, 1995
18. **Lee AWM,\*** Foo W, Poon YF, Law SCK, Chan DKK, O SK, Tung SY, Ho JHC. Staging of Nasopharyngeal Carcinoma: Evaluation of N-Staging by Ho and UICC/AJCC System. *Clin Oncol*, 8(3):146-154, 1996
19. **Lee AWM,\*** Foo W, Law SCK, O SK, Tung SY, Sze WM, Lau WH. N-Staging of Nasopharyngeal Carcinoma: Discrepancy between UICC/AJCC and Ho's System. *Clin Oncol*, 8(3):155-159, 1996
20. **Lee AWM,** Foo W, Law SCK, Poon YF, Sze WM, O SK, Tung SY, Lau WH. Nasopharyngeal Carcinoma: Presenting Symptoms and Duration before Diagnosis. *HK Med J*, 3(4):335-361, 1997
21. **Lee AWM,\*** Foo W, Law SCK, Poon YF, Sze WM, Tung SY, Lau WH. Reirradiation for Recurrent Nasopharyngeal Carcinoma: Factors Affecting the Therapeutic Ratio and Ways for Improvement. *Int J Radiat Oncol Biol Phys*, 38(1):43-52, 1997
22. Cheung F, Pang SW, Hioe F, Cheung KN, **Lee AWM,** Yau TK. Nnasopharyngeal Carcinoma in Situ: Two Cases of an Emerging Diagnostic Entity. *Cancer*, 83(6):1069-1073, 1998
23. **Lee AWM,\*** Foo W, Chappell R, Fowler JF, Sze WM, Poon YF, Law SCK, Ng SH, O SK, Tung SY, Lau WH, Ho JHC. Effect of Time, Dose, and Fractionation on Temporal Lobe Necrosis following Radiotherapy for Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*, 40(1):35-42, 1998
24. **Lee AWM,** Ko WM, Foo W, Choi P, Tung Y, Sham J, Cheng B, Au G, Lau WH, Choy D, O SK, Sze WM, Tse KC, Law CK, Teo P, Yau TK, Kwan WH. Nasopharyngeal Carcinoma: Time Lapse before Diagnosis and Treatment. *HK Med J*, 4:132-136, 1998
25. **Lee AWM.** Recurrent Nasopharyngeal Carcinoma: The Puzzles of Long Latency: Regarding Lee AWM, et al, *IJROBP* 44:149-156; 1999 - Response. *Int J Radiat Oncol Biol Phys*, 45(5):1359-1359, 1999
26. **Lee AWM.** Regarding, Teo, Kwan, Chan et al, *IJROBP* 40:897-913, 1998. *Int J Radiat Oncol Biol Phys*, 43(5):1167-1167, 1999
27. **Lee AWM,\*** Foo W, Law SCK, Poon YF, O SK, Tung SY, Sze WM, Chappell R, Lau WH, Ho JHC. Staging of Nasopharyngeal Carcinoma: From Ho's to the New UICC System. *IJC*, 84(2):179-187, 1999
28. **Lee AWM,\*** Foo W, Law SCK, Poon YF, Sze WM, Tung SY, Chappell R, Lau WH, Ho JHC. Recurrent Nasopharyngeal Carcinoma: The Puzzles of Long Latency. *Int J Radiat Oncol Biol Phys*, 44(1):149-156, 1999

29. **Lee AWM,\*** Sze WM, Fowler JF, Chappell R, Leung SF, Teo P. Caution on the Use of Altered Fractionation for Nasopharyngeal Carcinoma. *Radiother Oncol*, 52(3):207-211, 1999
30. Sze WM, **Lee AWM**. Radiotherapy and Chemotherapy for Cervical Cancer. *J HK College of Radiologists*, 2(2):76-86, 1999
31. **Lee AWM,\*** Foo W, Law SCK, Peters LJ, Poon YF, Chappell R, Sze WM, Tung SY, Lau WH, Ho JHC. Total Biological Effect on Late Reactive Tissues following Reirradiation for Recurrent Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*, 46(4):865-872, 2000
32. Wai HPS, Yau TK, Sze WM, Yeung MW, Hioe F, **Lee AWM**. Metastatic Tumour of the Tunica Vaginalis Testis from Carcinoma of The Stomach. *Int J Clin Practice*, 54(10):685-686, 2000
33. Wai HPS, Yau TK, Sze WM, Yeung MW, **Lee AWM**. Quadruple Primary Neoplasms in A 27-Year-Old Woman. *Hospital Med*, 61(2):138-139, 2000
34. Yu CLM, Fielding R, Chan CLW, Tse VKC, Choi PHK, Choy DTK, O SK, **Lee AWM**, Sham JST. Measuring Quality of Life of Chinese Cancer Patients – A Validation of the Chinese Version of the Functional Assessment of Cancer Therapy-General (Fact-G) Scale. *Cancer*, 88(7):1715-1727, 2000
35. Lau KY, Fung WT, Chan PO, Sze WM, **Lee AWM**, Yau TK. MRI of the Hypothalamus and Pituitary Gland in Patients with Hyperprolactinaemia following Radiotherapy for Nasopharyngeal Carcinoma. *Singapore Med J*, 42(9):406-409, 2001
36. **Lee AWM,\*** Sze WM, Yau TK, Yeung RMW, Chappell R, Fowler JF. Retrospective Analysis on Treating Nasopharyngeal Carcinoma with Accelerated Fractionation (6 Fractions per Week) in Comparison with Conventional Fractionation (5 Fractions per Week.): Report on 3-Year Tumor Control and Normal Tissue Toxicity. *Radiother Oncol*, 58(2):121-130, 2001
37. Wai HPS, Yeung RMW, Sze WM, Yau TK, **Lee AWM**. A Review of Superior Vena Cava Obstruction in Hong Kong Chinese Patients. *J HK College of Radiologists*, 4:143-145, 2001
38. **Lee AWM,\*** Kwong DLW, Leung SF, Tung SY, Sze WM, Sham JST, Teo PML, Leung TW, Wu PM, Chappell R, Peters LJ, Fowler JF. Factors Affecting Risk of Symptomatic Temporal Lobe Necrosis: Significance of Fractional Dose and Treatment Time. *Int J Radiat Oncol Biol Phys*, 53(1):75-85, 2002
39. Yau TK, Lau Y, Kong J, Yeung MW, Chan M, Sze WM, Cheung P, Lim BH, **Lee AWM**. Breast Conservation Treatment in Hong Kong – Early Results of 203 Patients: Retrospective Study. *HK Med J*, 8:322-328, 2002
40. **Lee AWM.\*** Contribution of Radiotherapy to Function Preservation and Cancer Outcome in Primary Treatment of Nasopharyngeal Carcinoma. *World J Surg*, 27(7):838-843, 2003
41. **Lee AWM,\*** Foo W, Mang O, Sze WM, Chappell R, Lau WH, Ko WM. Changing Epidemiology of Nasopharyngeal Carcinoma in Hong Kong over a 20-Year Period (1980-99): An Encouraging Reduction in both Incidence and Mortality. *IJC*, 103(5):680-685, 2003
42. Lau KY, Kan WK, Sze WM, **Lee AWM**, Chan JKW, Yau TK, Yeung RM, Tan LTH, Chan PO, Lee ASL. Magnetic Resonance for T-Staging of Nasopharyngeal Carcinoma - The Most Informative Pair of Sequences. *Jpn J Clin Oncol*, 34(4):171-175, 2004

43. Lau KY, Kan WK, Sze WM, **Lee AWM**, Yau TK, Tan LTH, Chan PO. Accuracy of Nasopharyngeal Carcinoma Staging by Magnetic Resonance Imaging. *Aust Radiol*, 48(1):14-16, 2004
44. **Lee AWM**,\* Au JSK, Teo PML, Leung TW, Chua DTT, Sze WM, Zee BCY, Law SCK, Leung SF, Tung SY, Kwong DLW, Lau WH. Staging of Nasopharyngeal Carcinoma: Suggestions for Improving the Current UICC/AJCC Staging System. *Clin Oncol*, 16(4):269-276, 2004
45. Sze WM, **Lee AWM**, Tong M, Ng C, Soong I, Chan K, Yeung R, Yau TK. Preliminary Experience on Treating Advanced Nasopharyngeal Carcinoma (NPC) Affecting/Abutting Neurological Structures with Induction Chemotherapy followed by Concurrent Chemo-Radiation with Accelerated Fractionation. *JCO*, 22(14):494S-494S, 2004
46. Sze WM, **Lee AWM**, Yau TK, Yeung RMW, Lau KY, Leung SKC, Hung AWM, Lee MCH, Chappell R, Chan K. Primary Tumor Volume of Nasopharyngeal Carcinoma: Prognostic Significance for Local Control. *Int J Radiat Oncol Biol Phys*, 59(1):21-27, 2004
47. Soong IS, Yau TK, Ho CM, Lim BH, Leung S, Yeung RMW, Sze WM, **Lee AWM**. Post-Mastectomy Radiotherapy after Immediate Autologous Breast Reconstruction in Primary Treatment of Breast Cancers. *Clin Oncol*, 16(4):283-289, 2004
48. Yau TK, Sze WM, **Lee AWM**, Yeung MW, Leung KC, Hung WM, Chan WI. Effectiveness of Brachytherapy and Fractionated Stereotactic Radiotherapy Boost for Persistent Nasopharyngeal Carcinoma. *Head & Neck*, 6(12):1024-1030, 2004
49. **Lee AWM**. A Tribute to the Emperor Extraordinaire: The Legend of John H. C. Ho. *J HK College of Radiologists*, 8:117-120, 2005
50. Ng WT, Yau TK, Yung RWH, Sze WM, Tsang AHL, Law ALY, **Lee AWM**. Screening for Family Members of Patients with Nasopharyngeal Carcinoma. *IJC*, 113(6):998-1001, 2005
51. Le QT, Jones CD, Yau TK, Shirazi HA, Wong PH, Thomas EN, Patterson BK, **Lee AWM**, Zehnder JL. A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels In Patients with Nasopharyngeal Carcinoma. *Cancer Research*, 11(16):5700-5707, 2005
52. Sze WM, **Lee AWM**. In Regards to Sze et al.: Primary Tumor Volume of Nasopharyngeal Carcinoma: Prognostic Significance for Local Control (*IJROBP* 2004: 59:21-27) - Response. *Int J Radiat Oncol Biol Phys*, 61(2):629-629, 2005
53. Yu KH, Leung SF, Tung SY, Zee B, Chua DTT, Sze WM, Law SCK, Kam MKM, Leung TW, Sham JST, **Lee AWM**, Au JSK, Hui EP, Sze WK, Cheng ACK, Yau TK, Ngan RKC, Wong FCS, Au GKH, Chan ATC. Survival Outcome of Patients with Nasopharyngeal Carcinoma with First Local Failure: A Study by the Hong Kong Nasopharyngeal Carcinoma Study Group. *Head & Neck*, 27(5):397-405, 2005
54. **Lee AWM**,\* Sze WM, Au JSK, Leung SF, Leung TW, Chua DTT, Zee BCY, Law SCK, Teo PML, Tung SY, Kwong DLW, Lau WH. Treatment Results for Nasopharyngeal Carcinoma in the Modern Era: The Hong Kong Experience. *Int J Radiat Oncol Biol Phys*, 61(4):1107-1116, 2005
55. **Lee AWM**,\* Yau TK, Wong DHM, Chan EWK, Yeung RMW, Ng WT, Tong M, Soong IS, Sze WM. Treatment of Stage IV (A-B) Nasopharyngeal Carcinoma by Induction-Concurrent

- Chemoradiotherapy and Accelerated Fractionation. *Int J Radiat Oncol Biol Phys*, 63(5):1331-1338, 2005
56. **Lee AWM,\*** Lau WH, Tung SY, Chua DTT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JST, Ngan RKC, Law SCK, Yau TK, Au JSK, O'Sullivan B, Pang ESY, O SK, Au GKH, Lau JT. Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by The Hong Kong Nasopharyngeal Cancer Study Group. *JCO*, 23(28):6966-6975, 2005
  57. **Lee AWM.\*** A Tribute to the Father of Radiology and Oncology in Hong Kong – The Legend of John H. C. Ho, MD Obituary. *Int J Radiat Oncol Biol Phys*, 64(1):1-2, 2006
  58. Lee MCH, **Lee AWM**, Ling YH, Pang E, Ng WT, Hung AWM, Leung SKC, Chan DWI, Law ALY, Yau TK. Fitting of Biological Parameters for Tumor Control Probability of Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*, 66(3):S417-S418, 2006
  59. Yau TK, **Lee AWM**, Wong DHM, Yeung RMW, Chan EWK, Ng WT, Tong M, Soong IS. Induction Chemotherapy with Cisplatin and Gemcitabine followed by Accelerated Radiotherapy and Concurrent Cisplatin in Patients with Stage IV (A-B) Nasopharyngeal Carcinoma. *Head & Neck*, 28(10):880-887, 2006
  60. Teo PML, Leung SF, Tung SY, Zee B, Sham JST, **Lee AWM**, Lau WH, Kwan WH, Leung TW, Chua D, Sze WM, Au JSK, Yu KH, O SK, Kwong D, Yau TK, Law SCK, Sze WK, Au G, Chan ATC. Dose-Response Relationship of Nasopharyngeal Carcinoma above Conventional Tumoricidal Level: A Study by The Hong Kong Nasopharyngeal Carcinoma Study Group (HKNPCSG). *Radiother Oncol*, 79(1):27-33, 2006
  61. **Lee AWM,\*** Tung SY, Chan ATC, Chappell R, Fu YT, Lu TX, Tan T, Chua DTT, O'Sullivan B, Xu SL, Pang ESY, Sze WM, Leung TW, Kwan WH, Chan PTM, Liu XF, Tan EH, Sham JST, Siu L, Lau WH. Preliminary Results of A Randomized Study (NPC-9902 Trial) on Therapeutic Gain by Concurrent Chemotherapy and/or Accelerated Fractionation for Locally Advanced Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*, 66(1):142-151, 2006
  62. Yau TK, Chan K, Chan M, Lau HW, Soong IS, Cheung P, Chang ATY, **Lee AWM**. Wide Local Excision and Radiotherapy for the Treatment of Ductal Carcinoma in Situ of The Breast: The Hong Kong Experience. *Clin Oncol*, 18(6):447-452, 2006
  63. Yau TK, **Lee AWM**, Wong DHM, Pang ESY, Ng WT, Yeung RMW, Soong IS. Treatment of Stage IV (A-B) Nasopharyngeal Carcinoma by Induction-Concurrent Chemoradiotherapy and Accelerated Fractionation: Impact of Chemotherapy Schemes. *Int J Radiat Oncol Biol Phys*, 66(4):1004-1010, 2006
  64. Choi CY, Ng WT, Chang ATY, Soong IS, **Lee AWM**. Analysis of Cervical Cancer in Chinese Patients Treated with Chemoradiation or Radiotherapy Alone. *J HK College of Radiologists*, 10(2):51-58, 2007
  65. **Lee AWM**. In Regards to Chen et al.: Experience in Fractionated Stereotactic Body Radiation Therapy Boost for Newly Diagnosed Nasopharyngeal Carcinoma (IJROBP 2006; 66:1408-1414). *Int J Radiat Oncol Biol Phys*, 68(5):1584-1585, 2007
  66. **Lee AWM**. Nasopharyngeal Cancer: Advances in Radiotherapy. *Int J Radiat Oncol Biol Phys*, 69(2):S115-S117, 2007

67. Ng WT, **Lee AWM**, Kan WK, Chan J, Pang ESY, Yau TK, Lau KY. N-Staging by Magnetic Resonance Imaging for Patients with Nasopharyngeal Carcinoma: Pattern of Nodal Involvement by Radiological Levels. *Radiother Oncol*, 82(1):70-75, 2007
68. Yau TK, Soong IS, Chan K, Chan M, Cheung P, Lau HW, Chang ATY, **Lee AWM**. Clinical Outcome of Breast Conservation Therapy for Breast Cancer in Hong Kong: Prognostic Impact of Ipsilateral Breast Tumor Recurrence and 2005 St. Gallen Risk Categories. *Int J Radiat Oncol Biol Phys*, 68(3):667-672, 2007
69. **Lee AWM**,\* Lau KY, Hung WM, Ng WT, Lee MCH, Choi CW, Chan CCC, Tung R, Cheng PTC, Yau TK. Potential Improvement of Tumor Control Probability by Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma. *Radiother Oncol*, 87(2):204-210, 2008
70. Ng WT, Chan SH, **Lee AWM**, Lau KY, Yau TK, Hung WM, Lee MCH, Choi CW. Parapharyngeal Extension of Nasopharyngeal Carcinoma: Still a Significant Factor in Era of Modern Radiotherapy? *Int J Radiat Oncol Biol Phys*, 72(4):1082-1089, 2008
71. Yau TK, Soong IS, Chan K, Chang A, Sze H, Yeung MW, Tung R, Lau S, **Lee AWM**. Evaluation of the Prognostic Value of 2005 St. Gallen Risk Categories for Operated Breast Cancers in Hong Kong. *Breast*, 17(1):58-63, 2008
72. Yau TK, Sze H, Soong I, Hioe F, Khoo US, **Lee AWM**. HER2 Overexpression of Breast Cancers in Hong Kong: Prevalence and Concordance between Immunohistochemistry and In-Situ Hybridization Assays. *HK Med J*, 14(2):130-135, 2008
73. Yau TK, Sze H, Soong I, Wong W, Chan K, Chang A, Lau K, **Lee AWM**. Surveillance Mammography after Breast Conservation Therapy in Hong Kong: Effectiveness and Feasibility of Risk-Adapted Approach. *Breast*, 17(2):132-137, 2008
74. Ng WT, Choi CW, Lee MCH, Chan SH, Yau TK, **Lee AWM**. Familial Nasopharyngeal Carcinoma in Hong Kong: Epidemiology and Implication in Screening. *Familial Cancer*, 8(2):103-108, 2009
75. Yau TK, Choi CW, Sze H, Soong IS, **Lee AWM**. Should Young Age be a Contraindication to Breast Conservation Treatment in Chinese Women? Twelve-Year Experience from A Public Cancer Centre in Hong Kong. *HK Med J*, 15(2):94-99, 2009
76. Yau TK, Ng TY, Soong IS, Choi CW, Lam KO, Ng AWY, **Lee AWM**, Tung Y. Toxicity of Docetaxel Plus Cyclophosphamide as Adjuvant Therapy for Breast Cancer in Chinese Patients – The Hong Kong Experience. *Asia Pacific J Clin Oncol*, 5(2):123-128, 2009
77. **Lee AWM**,\* Ng WT, Hung WM, Choi CW, Tung R, Ling YH, Cheng PTC, Yau TK, Chang ATY, Leung SKC, Lee MCH, Bentzen SM. Major Late Toxicities after Conformal Radiotherapy for Nasopharyngeal Carcinoma – Patient and Treatment-Related Risk Factors. *Int J Radiat Oncol Biol Phys*, 73(4):1121-1128, 2009
78. Chan SH, Ng WT, Kam KL, Lee MCH, Choi CW, Yau TK, **Lee AWM**, Chow SK. Sensorineural Hearing Loss after Treatment of Nasopharyngeal Carcinoma: A Longitudinal Analysis. *Int J Radiat Oncol Biol Phys*, 73(5):1335-1342, 2009



79. Yau TK, Soong IS, Sze H, Choi CW, Yeung MW, Ng WT, **Lee AWM**. Trends and Patterns of Breast Conservation Treatment in Hong Kong: 1994-2007. *Int J Radiat Oncol Biol Phys*, 74(1):98-103, 2009
80. Chan OSH, Hung AWM, Lee MCH, Chang ATY, Yeung RMW, **Lee AWM**. The Superiority of Hybrid-Rapidarc Radiotherapy Technique in the Treatment of Advanced Non-Small Cell Lung Cancer: A Planning Study. *Int J Radiat Oncol Biol Phys*, 78(3):S814-S815, 2010
81. **Lee AWM**,\* Tung SY, Chua DTT, Ngan RKC, Chappell R, Tung R, Siu L, Ng WT, Sze WK, Au GKH, Law SCK, O'Sullivan B, Yau TK, Leung TW, Au JSK, Sze WM, Choi CW, Fung KK, Lau JT, Lau WH. Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. *J NCI*,102(15):1188-1198, 2010
82. Ng WT, Choi CW, Lee MCH, Law LY, Yau TK, **Lee AWM**. Outcomes of Nasopharyngeal Carcinoma Screening for High Risk Family Members in Hong Kong. *Familial Cancer*, 9(2):221-228, 2010
83. Ng DCK, Wong SKH, Ng WT, **Lee AWM**, Li MKW. Impact of Adjuvant Chemoradiation for Adenocarcinoma of Stomach after Curative Gastrectomy in Chinese: A 7-Year Audit. *Surg Practice*, 14(3):85-91, 2010
84. Yau TK, Choi CW, Ng E, Yeung R, Soong IS, **Lee AWM**. Delay in Presentation of Symptomatic Breast Cancer in Hong Kong – Experience in A Public Cancer Center. *HK Med J*, 16(5):373-377, 2010
85. **Lee AWM**, Yau TK, Shum TC, Ng WT, Chan LL, Yeung RM. A Phase II Study of Pemetrexed Combined with Cisplatin in Patients (Pts) with Recurrent or Metastatic Nasopharyngeal Carcinoma. *JCO*, DOI:10.1016/j.oraloncology.2011./2.001, 2011
86. Tse VC, Ng WT, Lee V, **Lee AWM**, Chua DTT, Chau J, McGhee SM. Cost-Analysis of XELOX and FOLFOX4 for Treatment of Colorectal Cancer to Assist Decision-Making on Reimbursement. *BMC Cancer*, 11:288, 2011
87. **Lee AWM**,\* Tung SY, Ngan RKC, Chappell R, Chua DTT, Lu TX, Siu L, Tan T, Chan LK, Ng WT, Leung TW, Fu YT, Au GKH, Zhao C, O'Sullivan B, Tan EH, Lau WH. Factors Contributing to the Efficacy of Concurrent-Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: Combined Analyses of NPC-9901 And NPC-9902 Trials. *Eu J Cancer*, 47(5):656-666, 2011
88. Choi CW, Lee MCH, Ng WT, Law LY, Yau TK, **Lee AWM**. An Analysis of the Efficacy of Serial Screening for Familial Nasopharyngeal Carcinoma Based on Markov Chain Models. *Familial Cancer*, 10(1):133-139, 2011
89. Chang ATY, Ng WT, Law ALY, Ku KM, Lee MCH, **Lee AWM**. Adjuvant Chemoradiation for Resected Gastric Cancer: A 10-Year Experience. *Gastric Cancer*, 14(1):63-71, 2011
90. Ng WT, Lee MCH, Hung WM, Choi CW, Lee KC, Chan OSH, **Lee AWM**. Clinical Outcomes and Patterns of Failure after Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys*, 79(2):420-428, 2011

91. Chan SH, Cheung FMF, Ng WT, Choi CW; Cheung KN, Yiu KH, **Lee AWM**. Can the Analysis of ERCC1 Expression Contribute to Individualized Therapy in Nasopharyngeal Carcinoma? *Int J Radiat Oncol Biol Phys*, 79(5):1414-1420, 2011
92. **Lee AWM**,\* Tung SY, Chan ATC, Chappell R, Fu YT, Lu TX, Tan T, Chua DTT, O'Sullivan B, Tung R, Ng WT, Leung TW, Leung SF, Yau S, Zhao C, Tan EH, Au GKH, Siu L, Fung KK, Lau WH. A Randomized Trial on Addition of Concurrent-Adjuvant Chemotherapy and/or Accelerated Fractionation for Locally-Advanced Nasopharyngeal Carcinoma. *Radiother Oncol*, 98(1):15-22, 2011
93. Chan OSH, Lee MCH, Hung AWM, Chang ATY, Yeung RMW, **Lee AWM**. The Superiority of Hybrid-Volumetric Arc Therapy (VMAT) Technique over Double Arcs VMAT and 3D-Conformal Technique in the Treatment of Locally Advanced Non-Small Cell Lung Cancer – A Planning Study. *Radiother Oncol*, 101(2):298-302, 2011
94. Chan OSH, Yeung RMW, Hung AWM, Lee MCH, Chang ATY, Chan CCC, **Lee AWM**. Stereotactic Ablative Radiotherapy for Medically Inoperable Early Stage Lung Cancer: Early Outcomes. *HK Med J*, 18(5):412-418, 2012
95. Lee AWM,\* Fee WE Jr, Ng WT, Chan LK. Nasopharyngeal Carcinoma: Salvage of Local Recurrence. *Oral Oncol*, 48(9):768-774, 2012
96. **Lee AWM**,\* Lin JC, Ng WT. Current Management of Nasopharyngeal Cancer. *Seminars in Radiat Oncol*, 22(3):233-244, 2012
97. **Lee AWM**,\* Ng WT, Chan YH, Sze H, Chan C, Lam TH. The Battle Against Nasopharyngeal Cancer. *Radiother Oncol*, 104(3):272-278, 2012
98. Ting CM, Wong CKC, Wong RNS, Lo KW, **Lee AWM**, Tsao GSW, Lung ML, Mak NK. Role of STAT3/5 and BCL-2/X1 in 2-Methoxyestradiol-Induced Endoreduplication of Nasopharyngeal Carcinoma Cells. *Molecular Carcinogenesis*, 51(12):963-972, 2012
99. Huang Z, Cheng Y, Chiu PM, Cheung FMF, Nicholls JM, Kwong DLW, **Lee AWM**, Zabarovsky ER, Stanbridge EJ, Lung HL, Lung ML. Tumor Suppressor Alpha B-Crystallin (CRYAB) Associates with the Cadherin/Catenin Adherens Junction and Impairs NPC Progression-Associated Properties. *Oncogene*, 31(32):3709-3720, 2012
100. Chen H, Ko JMY, Wong VCL, Hyytiainen M, Keski-Oja J, Chua D, Nicholls JM, Cheung FMF, **Lee AWM**, Kwong DLW, Chiu PM, Zabarovsky ER, Tsao SW, Tao Q, Kan R, Chan SHK, Stanbridge EJ, Lung ML. LTBP-2 Confers Pleiotropic Suppression and Promotes Dormancy in a Growth Factor Permissive Microenvironment in Nasopharyngeal Carcinoma. *Cancer Lett*, 325(1):89-98, 2012
101. Sze HCK, Lee MCH, Hung WM, Yau TK, **Lee AWM**. Rapidarc Radiotherapy Planning for Prostate Cancer: Single-Arc and Double-Arc Techniques vs. Intensity-Modulated Radiotherapy. *Med Dosimetry*, 37(1):87-91, 2012
102. Law ALY, Ng WT, Lee MCH, Chan ATS, Fung KH, Li F, Lao WC, **Lee AWM**. Treatment of Primary Liver Cancer Using Highly-Conformal Radiotherapy with KV-Image Guidance and Respiratory Control. *Radiother Oncol*, 102(1):56-61, 2012
103. **Lee AWM**,\* Ng WT, Chan LK, Chan OSH, Hung WM, Chan CC, Cheng PTC, Sze H, Lam TS, Yau TK. The Strength/Weakness of the AJCC/UICC Staging System (7th Edition) for

- Nasopharyngeal Cancer and Suggestions for Future Improvement. *Oral Oncol*, 48(10):1007-1013, 2012
104. **Lee AWM,\*** Ng WT, Chan OSH, Sze H. If Concurrent-Adjuvant Chemoradiotherapy is Beneficial for Locoregionally Advanced Nasopharyngeal Carcinoma, would Changing the Sequence to Induction-Concurrent Achieve Better Outcome? *Radiat Oncol*, 1(2):107-115, 2012
  105. Sze HCK, Ng WT, Chan OSH, Shum TCY, Chan LLK, **Lee AWM**. Radical Radiotherapy For Nasopharyngeal Carcinoma In Elderly Patients: The Importance Of Co-Morbidity Assessment. *Oral Oncol*, 48(2):162-167, 2012
  106. Yau TK, Shum T, **Lee AWM**, Yeung MW, Ng WT, Chan L. A Phase II Study of Pemetrexed Combined with Cisplatin in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma. *Oral Oncol*, 48(5):441-444, 2012
  107. Cheung F, Chan O, Ng WT, Chan L. **Lee A**, Pang SW. The Prognostic Value of Histological Typing in Nasopharyngeal Carcinoma. *Oral Oncol*, 48(5):429-433, 2012
  108. Chan OSH, Yeung RMW, **Lee AWM**. Maintenance Therapy in Advanced Non-Small Cell Lung Cancer: A Prime-Time for Change? *Chin Med J*, 126(12):2390-2398, 2013
  109. **Lee AWM,\*** Sze H, Ng WT. Is Selective Neck Irradiation Safe for Node-Negative Nasopharyngeal Carcinoma? *Int J Radiat Oncol Biol Phys*, 85(4):902-903, 2013
  110. Luk YS, Shum JSF, Sze HCK, Chan LLK, Ng WT, **Lee AWM**. Predictive Factors and Radiological Features of Radiation-Induced Cranial Nerve Palsy in Patients with Nasopharyngeal Carcinoma following Radical Radiotherapy. *Oral Oncol*, 49(1):49-54, 2013
  111. Lau HY, Leung CM, Chan YH, **Lee AWM**, Kwong DLW, Lung ML, Lam TH. Secular Trends of Salted Fish Consumption and Nasopharyngeal Carcinoma: A Multi-Jurisdiction Ecological Study in 8 Regions from 3 Continents. *BMC Cancer*, 13:298, 2013
  112. Chan KC, Ting CM, Chan PS, Lo MC, Lo KW, Curry JE, Smyth T, **Lee AWM**, Ng WT, Tsao GSW, Wong RNS, Lung ML, Mak NK. A Novel HSP90 Inhibitor AT13387 Induces Senescence in EBV-Positive Nasopharyngeal Carcinoma Cells and Suppresses Tumor Formation. *Molecular Cancer*, 12, 2013
  113. Kam MKM, Wong FCS, Kwong DLW, Sze HCK, **Lee AWM**. Current Controversies in Radiotherapy for Nasopharyngeal Carcinoma (NPC). *Oral Oncol*, 50(10):907-912, 2014
  114. **Lee AWM,\*** Sze H, Lam KO, Chen X. A Tale of Two Cities in China: Hong Kong and Shenzhen. *Int J Radiat Oncol Biol Phys*, 89(4):704-708, 2014
  115. Ng WT, Lee MCH, Chang ATY, Chan OSH, Chan LLK, Cheung FY, Hung WM, Chan CC, **Lee AWM**. The Impact of Dosimetric Inadequacy on Treatment Outcome of Nasopharyngeal Carcinoma with IMRT. *Oral Oncol*, 50(5):506-512, 2014
  116. Ng WT, Yuen KT, Au KH, Chan OSH, **Lee AWM**. Staging of Nasopharyngeal Carcinoma – The Past, The Present and The Future. *Oral Oncol*, 50(6):549-554, 2014
  117. **Lee AWM,\*** Ng WT, Chan LLK, Hung WM, Chan CCC, Sze HCK, Chan OSH, Chang ATY, Yeung RM. Evolution of Treatment for Nasopharyngeal Cancer – Success and Setback in the Intensity-Modulated Radiotherapy Era. *Radiother Oncol*, 110(3):377-384, 2014
  118. Sun Y, Yu XL, **Lee AWM**, Wee JTS, Lee N Zhou GQ, Tang LL, Tao CJ, Guo R, Mao YP, Zhang R, Guo Y, Ma J. Recommendation for a Contouring Method and Atlas of Organs at Risk

- in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy. *Radiother Oncol*, 110(3):390-397, 2014
119. Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, **Lee A**, Le QT, Maingon P, Nutting CK, O'Sullivan B, Porceddu SV, Lengele B. Delineation of the Neck Node Levels for Head and Neck Tumors: A 2013 Update. DAHANCA, EORTC, HKNPCSF, NCIC, CTG, NCRI, RTOG, TROG Consensus Guidelines. *Radiother Oncol*, 110(1):172-181, 2014
  120. Sze H, Chan LLK., Ng WT, Hung AWM, Lee MCH, Chang ATY, Chan OSH, Cheung FY, Yeung RMW, **Lee AWM**. Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4? *Oral Oncol* 50:1188–1195; 2014
  121. **LEE AWM**, B Ma, Ng WT, Chan ATC. The management of nasopharyngeal carcinoma – current practice and future perspective. *J Clin Oncol*, 33:3356-3364, 2015
  122. **Lee A**,\* Ngan R, Tung S, Cheng A, Kwong D, Lu TX, Chan A, Chan L, Yiu H, Ng WT, Wong F, Yuen KT, Yau S, Cheung FY, Chan O, Choi H, Chappell R. Preliminary Results of NPC-0501 Trial to Evaluate the Therapeutic Gain by Changing Chemoradiotherapy Sequence from Concurrent-Adjuvant to Induction-Concurrent, Fluorouracil to Capecitabine, and Radiotherapy Fractionation from Conventional to Accelerated for Locoregionally Advanced Nasopharyngeal Carcinoma. *Cancer*, 121:1328-38; 2015
  123. Ng WT, Chang AT, Lee SW, Sze HC, **Lee AWM**.\* Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant. *Curr Treat Options Oncol*. Sep;16(9):361, 2015
  124. Strojjan P, Corry J, Eisbruch A, Vermorken JB, Mendenhall WM, **Lee AWM**, Haigentz M Jr, Beitler JJ, de Bree R, Takes RP, Paleri V, Kelly CG, Genden EM, Bradford CR, Harrison LB, Rinaldo A, Ferlito A. Recurrent and Second Primary Squamous Cell Carcinoma of the Head And Neck: When and How to Re-Irradiate. *Head & Neck*, 37(1):134-150, 2015
  125. Strojjan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr, Bossi P, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, **Lee AWM**, Harrison LB, Bradford CR, Smee R, Silver CE, Rinaldo A, Ferlito. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. *Head & Neck*, DOI:10.1002/hed.24026, 2015
  126. Sze HCK, Blanchard P, Ng WT, Pignon JP, **Lee AWM**.\* Chemotherapy for Nasopharyngeal Carcinoma – Current Recommendation and Controversies. *Hematology/Oncology Clinics of North America*, 29:1107-1122; 2015.
  127. Yang X, Dai W, Kwong DL, Szeto CYY, Wong EH, Ng WT, **Lee AWM**, Ngan RKC, Yau CC, Tung SY, Lung ML. Epigenetic markers for non-invasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. *IJC*, DOI: 10.1002/ijc.29192, 2015
  128. Chan KC, Chan LS, Ip JCY, Lo C, Yip TTC, Ngan RKC, Wong RNS, Lo KW, Ng WT, **Lee AWM**, Tsao GSW, Kahn M, Lung ML, Mak NK. Therapeutic targeting of CBP/b-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. *Scientific Reports* 5: 9979 | DOI: 10.1038/srep09979, 2015
  129. Dai W, Cheung AKL, Ko JMY, Cheng Y, Zheng H, Ngan RKC, Ng WT, **Lee AWM**, Yau CC, Lee VHF, Lung ML. Comparative methylome analysis in solid tumors reveals aberrant

- methylation at chromosome 6p in nasopharyngeal carcinoma. *Cancer Medicine* doi: 10.1002/cam4.451, 2015
130. Brouwer CL, Steenbakkens RJHM, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, **Lee A**, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NR G Oncology and TROG consensus guidelines. *Radiotherapy and Oncology*, 10.1016/j.radonc.2015.07.041, 2015
  131. Kan R, Shuen WH, Lung HL, Cheung AKL, Dai W, Kwong DLW, Ng WT, **Lee AWM**, Yau CC, Ngan RKC, Tung SY, Lung ML. NF- $\kappa$ B p65 Subunit Is Modulated by Latent Transforming Growth Factor- $\beta$  Binding. *PLOS ONE*, DOI:10.1371/journal.pone.0127239, 2015
  132. Blanchard P, **Lee A**, Marguet S, Leclercq J, Ng WT, Ma J, Chan ATC, Huang PY, Benhamou E, Zhu GP, Chua DTT, Chen Y, Mai HQ, Kwong DLW, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP, on behalf of the MAC-NPC Collaborative Group\*. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *Lancet Oncol* 2015; 16: 645–55, 2015
  133. Pan JJ, Ng WT, Zong JF, Chan LLK, O'Sullivan B, Lin SJ, Sze HCK, Chen YB, Choi HCW, Guo QJ, Kan WK, Xiao YP, W Xu, Le QT, Glastonbury CM, Colevas AD, Weber RS, Shah JP, **Lee AWM**.\* Proposal for the 8th Edition of AJCC/UICC Staging System for Nasopharyngeal Cancer in the Era of Intensity-Modulated Radiotherapy. *Cancer*, DOI: 10.1002/cncr.29795, 2015
  134. Lam KO, **Lee AWM**,\* Choi CW, Sze HCK, Zietman AL, Hopkins KI, Rosenblatt E. Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. *Int J Radiat Oncol Biol Phys*, DOI: 10.1016/j.ijrobp.2015.11.047, 2015
  135. Dai W, Zheng H, Cheung AK, Tang CS, Ko JM, Wong BW, Leong MM, Sham PC, Cheung F, Kwong DL, Ngan RK, Ng WT, Yau CC, Pan J, Peng X, Tung S, Zhang Z, Ji M, Chiang AK, **Lee AW**, Lee VH, Lam KO, Au KH, Cheng HC, Yiu HH, Lung ML. Whole-exome Sequencing Identifies MST1R as a Genetic Susceptibility Gene in Nasopharyngeal Carcinoma. *Proc Natl Acad Sci U S A*. 2016 Mar 22;113(12):3317-22. doi: 10.1073/pnas.1523436113
  136. Ka-On Lam, **Anne W. M. Lee**, Wai-Tong Ng, Kirsten I. Hopkins. The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment. *CCO*, Vol 5, No.2 (April 2016), 2016
  137. Strojjan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M Jr, Bossi P, Worden FP, Langendijk JA, Eisbruch A, Mendenhall WM, **Lee AW**, Harrison LB, Bradford CR, Smee R, Silver CE, Rinaldo A, Ferlito A. Cumulative Cisplatin Dose in Concurrent Chemoradiotherapy for Head and Neck Cancer: A Systematic Review. *Head & Neck*, 2016 Apr; 38 Suppl 1:E2151-8. doi: 10.1002/hed.24026
  138. Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL, Lin SJ, Guo QJ, Sze HC, Chen YB, Xiao YP, Kan WK, O'Sullivan B, Xu W, Le QT, Glastonbury CM, Colevas AD, Weber RS, Lydiatt W, Shah JP, **Lee AW**. Prognostic Nomogram for Refining the Prognostication of the Proposed 8th Edition of the AJCC/UICC Staging System for Nasopharyngeal Cancer in the Era of Intensity-modulated Radiotherapy. *Cancer*. 2016 Nov 15;122(21):3307-3315. doi: 10.1002/cncr.30198

139. Chai AW, Cheung AK, Dai W, Ko JM, Ip JC, Chan KW, Kwong DL, Ng WT, **Lee AW**, Ngan RK, Yau CC, Tung SY, Lee VH, Lam AK, Pillai S, Law S, Lung ML. Metastasis-suppressing NID2, an Epigenetically-silenced Gene, in the Pathogenesis of Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma. *Oncotarget*, 2016 Nov 29;7(48):78859-78871. doi: 10.18632/oncotarget.12889
140. Ribassin-Majed L, Marguet S, **Lee AW**, Ng WT, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilias G, Bourhis J, Pignon JP, Blanchard P. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. *J Clin Oncol*. 2016 Dec 5;JCO2016674119
141. Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, Sze CK, Ng S, Leung TW, **Lee A**. Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma. *Clinical Oncology (Royal College of Radiologists)*. 2016 Aug;28(8):e52-60. doi: 10.1016/j.clon.2016.05.004. Epub 2016 May 24.
142. Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, Leong MML, Deng M, Kwok TCT, J Chan, Kwong DLW, **Lee AWM**, Ng WT, Ngan RKC, Yau CC, Tung S, Lee VHF, Lam KO, Kwan CK, Li WS, Yau S, Chan KW, Lung ML. Whole-exome sequencing identifies multiple loss-of-function mutations of NF- $\kappa$ B pathway regulators in nasopharyngeal carcinoma. *Proc Natl Acad Sci*. 2016 Oct 4;113(40):11283-11288. Epub 2016 Sep 19.
143. Choi HC, Xu W, **Lee AW**. Reply to Nomograms need to be presented in full. *Cancer*. 2017 Jan 1;123(1):178-179. doi: 10.1002/cncr.30345. Epub 2016 Sep 14.
144. Chan OS, Sze HC, Lee MC, Chan LL, Chang AT, Lee SW, Hung WM, **Lee AW**, Ng WT. Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. *Head & Neck*. 2017 Mar;39(3):533-540. doi: 10.1002/hed.24645. Epub 2016 Nov 29.
145. Rotolo F, Pignon JP, Bourhis J, Marguet S, Leclercq J, Tong Ng W, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Soong YL, Moon J, Tung Y, Chi KH, Fountzilias G, Zhang L, Hui EP, **Lee AW**, Blanchard P\*, Michiels S\*; MAC-NPC Collaborative Group., on behalf of the MAC-NPC Collaborative Group. Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. *J Natl Cancer Inst*. 2017 Apr;109(4). pii: djw239. DOI: 10.1093/jnci/djw239, 2016
146. Lee VH, Kwong DL, Lam KO, Lai YC, Li Y, Tong CC, Ho PP, Chan WL, Wong LS, Leung DK, Chan SY, Chan FT, Leung TW, **Lee AW**. Metronomic Oral Cyclophosphamide as Third-line Systemic Treatment or Beyond in Patients With Inoperable Locoregionally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma. *Medicine (Baltimore)*. 2017 Apr;96(15):e6518. doi: 10.1097/MD.00000000000006518.
147. Chen YP, Chen L, Li WF, **Lee AWM**, Vermorken JB, Wee J, O'Sullivan B, Eisbruch A, Lin JC, Mai HQ, Zhang L, Guo Y, Lin AH, Sun Y, Ma J. Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma. *Int J Radiat*

- Oncol Biol Phys. 2017 May 1;98(1):170-176. doi: 10.1016/j.ijrobp.2017.01.214. Epub 2017 Jan 29.
148. Lee V, Kwong D, Leung TW, Lam KO, Tong CC, **Lee A**. Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma – How far have we achieved? *Crit Rev Oncol Hematol*. 2017 Jun;114:13-23. doi: 10.1016/j.critrevonc.2017.03.030. Epub 2017 Apr 2.
149. Li ji-shi, Xu Zhi-yuan, Chen Zhi-jian, Chen Zhi-jian, Xu Xiao-ping, Jing Hai-man, Zhou Lue, Chen Xian, Lam Ka-on and **Lee Wing-miu Anne**. A New Model of Clinical Pathway for Comprehensive Management of Nasopharyngeal Carcinoma: Research and Clinical Practice. *China Cancer*, 2017, 26(2), p106-110.
150. **Lee AWM**, Tung SY, Ng WT, Lee V, Ngan RKC, Choi HCW, Chan LLK, Siu LL, Ng AWY, Leung TW, Yiu HHY, O'Sullivan B, Chappell R. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. *Cancer* 2017 Nov 1;123(21):4147-4157, DOI: 10.1002/cncr.30850.
151. CL Chiang, TH So, ZJ Chen, VH Lee, **AW Lee**. Pursuit of Excellence in the Management of Nasopharyngeal Carcinoma (NPC). *International Journal of Head and Neck Science* 1(4): 199-211, 2017, DOI: 10.6696/IJHNS.2017.0104.01.
152. Strojjan P, Hutcheson KA, Eisbruch A, Beitler JJ, Langendijk JA, **Lee AWM**, Corry J, Mendenhall WM, Smee R, Rinaldo A, Ferlito A. Treatment of late sequelae after radiotherapy for head and neck cancer. *Cancer Treat Rev*. 2017 Sep;59:79-92. doi: 10.1016/j.ctrv.2017.07.003. Epub 2017 Jul 18.
153. Yue PYK, Ha WY, Lau CC, Cheung FMF, **Lee AWM**, Ng WT, Ngan RKC, Yau CC, Kwong DLW, Lung HL, Mak NK, Lung ML, Wong RNS. MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma. *Sci Rep*. 2017 Sep 20;7(1):12012. doi: 10.1038/s41598-017-10695-2.
154. Yang L, Lam KO, Lee VHF, **Lee AWM**. Gefitinib-induced toxic epidermal necrolysis in a patient with metastatic non-small cell lung cancer. *Hong Kong J Radiol* 2018; 21:e8-11, DOI: 10.12809/hkjr1816416.
155. **Lee AW**, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, Corry J, Grau C, Grégoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Soong YL, Tao Y, Yom SS, Wee JT. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. *Radiother Oncol*. 2018 Jan;126(1):25-36. doi: 10.1016/j.radonc.2017.10.032. Epub 2017 Nov 15.
156. Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, Eisbruch A, Feng M, Giralt J, Gupta T, Hamoir M, Helito JK, Hu C, Hunter K, Johansen J, Kaanders J, Laskar SG, **Lee A**, Maingon P, Mäkitie A, Micciche' F, Nicolai P, O'Sullivan B, Poitevin A, Porceddu S, Skłodowski K, Tribius S, Waldron J, Wee J, Yao M, Yom SS, Zimmermann F, Grau C. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT,

- SOMERA, SRO, SSHNO, TROG consensus guidelines. *Radiother Oncol.* 2018 Jan;126(1):3-24. doi: 10.1016/j.radonc.2017.10.016. Epub 2017 Nov 24.
157. Ng WT, Wong ECY, Lee VHF, Chan JYW, **Lee AWM**. Head and neck cancer in Hong Kong. *Japanese Journal of Clinical Oncology.* 2018 Jan 1;48(1):13-21. doi: 10.1093/jjco/hyx151.
158. Ng WT, Ngan RKC, Kwong DLW, Tung SY, Yuen KT, Kam MKM, Sze HCK, Yiu HHY, Chan LLK, Lung ML, **Lee AWM**. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. *Int J Radiat Oncol Biol Phys.* 2018 Mar 1;100(3):630-638. doi: 10.1016/j.ijrobp.2017.11.038. Epub 2017 Dec 1.
159. Kessel KA, **Lee AWM**, Bentzen SM, Vikram B, Nüsslin F, Combs SE. Editorial: Data Based Radiation Oncology-Design of Clinical Trials. *Front Oncol.* 2018 Feb 16;8:34. doi: 10.3389/fonc.2018.00034. eCollection 2018.
160. Fernández-Alvarez V, López F, Suárez C, Strojjan P, Eisbruch A, Silver CE, Mendenhall WM, Langendijk JA, Rinaldo A, **Lee AWM**, Beitler JJ, Smee Ivarez J, Ferlito A. Radiation-induced carotid artery lesions. *Strahlenther Onkol.* 2018 Aug;194(8):699-710. doi: 10.1007/s00066-018-1304-4. Epub 2018 Apr 20.
161. Lee VHF, Chan SY, Tong CC, Lam KO, Kwong DLW, **Lee AWM**, Leung TW. New hope for advanced nasopharyngeal cancer – an Epstein-Barr virus-driven endemic malignancy? *Trans Cancer Res*, February 2018, 7(Supp 1): S53-S57, DOI: 10.21037/tcr.2017.12.25
162. Lam PL, Lam TC, Choi CW, **Lee AW**, Yuen KK, Leung TW. The impact of palliative care training for oncologists and integrative palliative service in a public-funded hospital cluster-a retrospective cohort study. *Support Care Cancer.* 2018 May;26(5):1393-1399. Doi: 10.1007/s00520-017-3963-6.
163. Ng WT, Tung SY, Lee V, Ngan RKC, Choi HCW, Chan LLK, Leung TW, Siu LL, Lu TX, Tan T, Tan EH, Sze HCK, Ng AWY, Yiu HHY, O'Sullivan B, Chappell R, **Lee AWM**. Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio. *Int J Radiat Oncol Biol Phys.* 2018 Aug 1;101(5):1078-1086. doi: 10.1016/j.ijrobp.2018.04.069. Epub 2018 May 2
164. Mai ZM, Lin JH, Chiang SC, Ngan RK, Kwong DL, Ng WT, Ng AW, Yuen KT, Ip KM, Chan YH, **Lee AW**, Ho SY, Lung ML, Lam TH. Test-retest reliability of a computer-assisted self-administered questionnaire on early life exposure in a nasopharyngeal carcinoma case-control study. *Scientific reports.* 2018 May 4; 8:7052, DOI: 10.1038/s41598-018-25046y.
165. Ko JMY, Tsang KHK, Dai W, Choi SSA, Leong MML, Ngan RKC, Kwong DLWS, Cheng A, **Lee AWM**, Ng WT, Tung S, Lee VHF, Lam KO, Chan CKC, Lung ML. Leukocyte telomere length associates with Nasopharyngeal risk and survival in Hong Kong Chinese. *Int J Cancer.* 2018 Nov 1;143(9):2289-2298. doi: 10.1002/ijc.31617. Epub 2018 Aug 7.
166. Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, Lee VHF, Tung SY, Chan ATC, Henry CK Sze HCK, Cheng ACK, **Lee AWM**, Kwong DLW, Anthony HP Tam AHP. Treatment Outcomes of Nasopharyngeal carcinoma in modern era after Intensity Modulated Radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study) *Oral Oncol* 2018;77:16-21, DOI: 10.1016/j.oraloncology.2017.12.004.



167. Liu X, Zhang I, Tang LL, Le QT, Chua MLK, Wee JTS, Lee NY, O'Sullivan B, **Lee AWM**, Sun Y, Ma J. Characteristics of Radiotherapy Trials Compared with other Oncological Clinical Trials in the Past 10 Years. *Jama Oncology*. 2018 Aug 1;4(8):1073-1079. doi: 10.1001/jamaoncol.2018.0887.
168. Lee VH, Kwong DL, Leung TW, Choi CW, O'Sullivan B, Lam KO, Lai V, Khong PL, Chan SK, Ng CY, Tong CC, Ho PP, Chan WL, Wong LS, Leung DK, Chan SY, So TH, Luk MY, **Lee AW**. The addition of pretreatment plasma Epstein-Barr virus DNA into the 8th edition of nasopharyngeal cancer TNM stage classification. *Int J Cancer*, 2018 Sept 7. DOI: 10.1002/ijc.31856.
169. Lee VH, Kwong DL, Leung TW, Choi HCW, O'Sullivan B, Lai V, Lam KO, Tong CC, Ng CY, Chan SY, Ho PP, Chan WL, Leung DK, Chan SK, Tsang KC, Khong PL, Luk MY, **Lee AW**. 5-Year Results of the Prognostic Roles of Serial Post-Intensity-Modulated Radiation Therapy Undetectable Plasma EBV DNA for Non-Metastatic Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology Biology Physics*, 2018 Nov. DOI: 10.1016/j.ijrobp.2018.06.315.
170. Lee VH, Lam KO, Chang AT, Lam TC, Chiang CL, So TH, Choi CW, **Lee AW**. Management of Nasopharyngeal Carcinoma: Is Adjuvant Therapy Needed? *J Oncol Pract*. 2018 Oct;14(10):594-602. doi: 10.1200/JOP.18.00219.
171. Le QT, Yom SS, Wee JTS, **Lee AWM**, Grau C, Grégoire V, Porceddu S, Welch JJ, Mehanna H. In Regard to Beadle and Anderson. *Int J Radiat Oncol Biol Phys*. 2018 Sep 1;102(1):229-230. doi: 10.1016/j.ijrobp.2018.05.015. Epub 2018 Aug 8.
172. Mendenhall WM, Suárez C, Genden EM, de Bree R, Strojan P, Langendijk JA, Mäkitie AA, Smee R, Eisbruch A, **Lee AWM**, Rinaldo A, Ferlito A. Parameters Associated With Mandibular Osteoradionecrosis. *Am J Clin Oncol*. 2018 Dec;41(12):1276-1280. doi: 10.1097/COC.0000000000000424. PubMed PMID: 29360644.
173. Chan LS, Man OY, Kwok HH, Chen L, Chan KC, Lung HL, Ngan RK, Wong RN, Lo KW, **Lee AW**, Tsao GS, Kahn M, Lung ML, Mak NK. The Wnt modulator ICG-001 mediates the inhibition of nasopharyngeal carcinoma cell migration in vitro via the miR-150/CD44 axis. *Int J Oncol*. 2019 Mar;54(3):1010-1020. doi: 10.3892/ijo.2018.4664. Epub 2018 Dec 12.
174. Mendenhall WM, Strojan P, Beitler JJ, Langendijk JA, Suarez C, **Lee AW**, Rinaldo A, Rodrigo JP, Smee R, Eisbruch A, Harrison LB, Corry J, Ferlito A. Radiotherapy for parapharyngeal space tumors. *Am J Otolaryngol*. 2019 Mar - Apr;40(2):289-291. doi: 10.1016/j.amjoto.2018.12.010. Epub 2018 Dec 21.
175. Ruyscher DD, Niedermann G, Burnet N, Siva S, **Lee AWM**, Hegi F. Radiotherapy toxicity. *Nature Reviews Disease Primers*. 2019 Feb 21;5(1):13. doi: 10.1038/s41572-019-0064-5.
176. Thu Le Q, Dimitrios Colevas A, O'Sullivan B, **Lee AWM**, Lee N, Ma B, Siu LL, Waldron J, Lim CM, Riaz N, Lynn J, Malik S. Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. *J Natl Cancer Inst*. 2019 Mar 26. pii: djz044. doi: 10.1093/jnci/djz044.
177. Mai ZM, Lin JH, Ngan RKC, Kwong DLW, Ng WT, Ng AWY, Yuen KT, Ip DKM, Chan YH, **Lee AWM**, Ho SY, Lung ML, Lam TH. Milk consumption across life periods in relation to lower

- risk of nasopharyngeal carcinoma: A multicentre case-control study. *Frontiers in Oncology*. 2019 Apr 10;9:253. doi: 10.3389/fonc.2019.00253. eCollection 2019.
178. Vardhanabhuti V.... **Lee AWM**... Radiomics Model to Predict Early Progression of Non-Metastatic Nasopharyngeal Carcinoma after Intensity-modulated Radiotherapy: A Multicenter Study. *Radiology: Artificial Intelligence*. In press.
  179. Brierley J, O'Sullivan B, Asamura H, Byrd D, Huang SH, **Lee AWM**, Piñeros M, Mason M, Moraes FY, Rösler W, Rous B, Torode J, Han van Krieken J, Gospodarowicz S. Global Consultation on Cancer Staging: promoting consistent understanding and use of cancer stage classification terminology. *Nature Reviews Clinical Oncology*. Accepted.
  180. Pang H, Wang X, Lam W, Vardhanabhuti V, **Lee AWM**, Yan K. Radiomics Analysis Using Stability Selection Supervised Component Analysis for Right-censored Survival Data. *Computer Methods and Programs in Biomedicine*. Submitted.
  181. .... **Lee AWM**... Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT – a study by the HKNPCSG. *Head & Neck*. Accepted.
  182. ~~Chan SK, Chan SY, Choi CW, Tong CC, Lam KO, Kwong DLW, Vardhanabhuti V, Leung TW, Luk MY, Lee AWM, Lee VHF. Prognostication of Half life Clearance of Plasma EBV DNA in Non-metastatic Nasopharyngeal Carcinoma Treated with Radical Intensity-modulated Radiation Therapy. *Cancer Epidemiology, Biomarkers & Prevention*. Submitted.~~ Chan SK, Chan SY, Choi CW, Tong CC, Lam KO, Kwong DLW, Vardhanabhuti V, Leung TW, Luk MY, **Lee AWM**, Lee VHF. Prognostication of half-life clearance of plasma EBV DNA in previously untreated non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy (TAM-19-07-311). *Therapeutic Advances in Medical Oncology*. Submitted.

**Presentations at Academic Conferences - Invited Lectures**

**International Conferences /Overseas Institutes**

1. Late temporal lobe brain necrosis following radiation therapy of nasopharyngeal carcinoma. The 1st Shanghai International Conference on Radiation Oncology, 29 April 1987, Shanghai, China. Lee AWM, et al. (Plenary Lecture) delivered by Ho JHC).
2. Complications of radiation therapy. Hong Kong Symposium on Nasopharyngeal Carcinoma. Asian Oceanian Clinical Oncology Association, 22 April 1990, Hong Kong.
3. Nasopharyngeal carcinoma: treatment results in Hong Kong. The 7<sup>th</sup> Asia-Oceanian Congress of Otorhinolaryngological Societies, 2-5 December 1991, Hong Kong.
4. Radiotherapy of head and neck: nasopharynx (Education Lecture). International Conference of Radiation Oncology, 21-25 June 1993, Kyoto, Japan.
5. Radiotherapy for nasopharyngeal carcinoma. The 2<sup>nd</sup> EORTC International Hong Kong Symposium on Current Trend in Cancer Care, 13 February 1995, Hong Kong.
6. Recurrent nasopharyngeal cancer: control and complications. Roentgen Centenary Congress and the 3<sup>rd</sup> Annual Scientific Meeting of Hong Kong College of Radiologists, 8-12 November 1995, Hong Kong.
7. Control of nasopharyngeal carcinoma by primary radiotherapy. Roentgen Centenary Congress and the 3<sup>rd</sup> Annual Scientific Meeting of Hong Kong College of Radiologists, 8-12 November 1995, Hong Kong.
8. Recurrent nasopharyngeal carcinoma revisited. The 2<sup>nd</sup> Hong Kong International Cancer Congress, 17-19 November 1995, Hong Kong.
9. Role of radiotherapy in management of cervical metastases. The 3<sup>rd</sup> Hong Kong International Cancer Congress, 13-16 November 1996, Hong Kong.
10. Radiotherapy of nasopharyngeal carcinoma. The 8<sup>th</sup> Overseas Meeting of the Royal College of Surgeons of Edinburgh Jointly with The College of Surgeons of Hong Kong, 27-30 October 1996, Hong Kong (read by Yau TK).
11. Nasopharyngeal cancer: effect of time dose fractionation on the therapeutic ratio. International Conference of Radiation Oncology, 5-7 June 1997, Beijing, China.
12. Staging and prognostic factors in nasopharyngeal cancer: the Hong Kong experience. UICC Workshop on Nasopharyngeal Cancer, 11-14 February 1998, Singapore.
13. The new AJCC/UICC staging system for nasopharyngeal cancer. Head and Neck Cancer Congress, 7-13 June 1998, Hong Kong/Beijing, China.
14. Treatment of nasopharyngeal carcinoma: lessons learnt from the past and challenges for the future (Education Lecture). Annual Meeting for the European Society on Therapeutic Radiation Oncology, 21-24 September 1998, Edinburgh, U.K.
15. Management of nasopharyngeal carcinoma – lessons learnt and challenges ahead. Stanford University Medical Center, October 1999, Palo Alto, U.S.A.
16. Pamela Youde Nethersole Eastern Hospital experience with 6 fractions per week radiotherapy (Instructional Course). 2000 International and 6<sup>th</sup> National Head and Neck Cancer Congress, 7 June 2000, Hong Kong.

17. Re-treatment of nasopharyngeal carcinoma – controversies and challenges (Instructional Course). 2000 International and 6<sup>th</sup> National Head and Neck Cancer Congress, 12 June 2000, Shanghai, China.
18. Nasopharyngeal carcinoma – controversies, re-treatment and new questions (Presidential Course). ASTRO 42<sup>nd</sup> Annual Meeting, 22-26 October 2000, Boston, U.S.A.
19. Management of nasopharyngeal carcinoma (Education Lecture). The 6<sup>th</sup> International Conference of Radiation Oncology, 31 January - 2 February 2001, Melbourne, Australia.
20. Clinical trials in developing countries – unique trial opportunity. The 6<sup>th</sup> International Conference of Radiation Oncology, 31 January - 2 February 2001, Melbourne, Australia.
21. Developments in management of nasopharyngeal carcinoma. The 8<sup>th</sup> Hong Kong International Cancer Congress, 26-28 October 2001, Hong Kong.
22. Recent advances in management of nasopharyngeal carcinoma. The 16<sup>th</sup> Asia Pacific Cancer Conference, 18-21 November 2001, Manila, Philippines.
23. Strategies for improving radiotherapy for nasopharyngeal carcinoma. The 4<sup>th</sup> Shanghai International Conference on Radiation Oncology, 20-22 May 2002, Shanghai, China.
24. Epidemiology of NPC – the world and local trends. The 10<sup>th</sup> ASEAN ORL Head & Neck Surgery Congress, 27-29 January 2003, Darussalam, Brunei.
25. Staging of nasopharyngeal carcinoma – critical review of the present AJCC/UICC system. The 10<sup>th</sup> ASEAN ORL Head and Neck Surgery Congress, 27-29 January 2003, Darussalam, Brunei.
26. Treatment strategies – The Hong Kong (Pamela Youde Nethersole Eastern Hospital) experience. The 10<sup>th</sup> ASEAN ORL Head and Neck Surgery Congress, 27-29 January 2003, Darussalam, Brunei.
27. Review of the AJCC/UICC 1997 Staging System for nasopharyngeal carcinoma – The Hong Kong (Pamela Youde Nethersole Eastern Hospital) experience. The 4<sup>th</sup> International UICC Symposium on Nasopharyngeal Carcinoma, 14-16 February 2003, Hong Kong.
28. Altered fractionation for NPC – benefits and harms. UICC NPC Workshop 2003 and the 4<sup>th</sup> International UICC Symposium on Nasopharyngeal Carcinoma, 14-16 February 2003, Hong Kong.
29. Overview of new treatment strategies for nasopharyngeal carcinoma. The 2003 International and 7<sup>th</sup> National Head & Neck Cancer Congress, 7-11 November 2003, Guangzhou, China.
30. Concurrent chemotherapy using cisplatin-based regimes for nasopharyngeal carcinoma. The 10<sup>th</sup> Hong Kong International Cancer Congress, 19-21 November 2003, Hong Kong.
31. Altered fractionation for nasopharyngeal carcinoma. The 2004 Symposium on Radiation Oncology, 8-10 April 2004, Shanghai, China.
32. Chemoradiation for NPC Patients. The 11<sup>th</sup> Hong Kong International Cancer Congress, 10-12 November 2004, Hong Kong.
33. Preliminary results of a prospective randomized study (NPC-9902 Trial) on the therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. East-West Symposium on Nasopharyngeal Carcinoma, 16-18 June 2005, Toronto, Canada.

34. Management for nasopharyngeal cancer (Education Lecture). The 13<sup>th</sup> Annual Meeting, European Cancer Conference, 31 October – 3 November 2005, Paris, France.
35. The Hong Kong story in the fight against nasopharyngeal cancer. The 11<sup>th</sup> Asian Oceanian Congress of Radiology, 6-9 August 2006, Hong Kong, China.
36. Combined modality treatment for nasopharyngeal carcinoma. 5<sup>th</sup> Shanghai International Conference on Radiation Oncology, 18-21 November 2006, Shanghai, China.
37. Nasopharyngeal Cancer: Advances in Radiotherapy. Multidisciplinary Head and Neck Cancer Symposium, 18-20 January 2007, Palm Springs, U.S.A.
38. Nasopharyngeal Cancer: Fascinating achievements and new challenges. East-West Symposium on Nasopharyngeal Carcinoma, 30 July – 2 August 2007, Sunshine Coast, Australia.
39. Nasopharyngeal Cancer (Educational Course). The 49<sup>th</sup> Annual Meeting of the American Society for Therapeutic Radiology and Oncology Meeting, 28 October – 1 November 2007, Los Angeles, U.S.A.
40. State of the art in Nasopharyngeal Cancer Treatment. International Union against Cancer, UICC World Cancer Congress, 27-32 August 2008, Geneva, Switzerland.
41. Nasopharyngeal Cancer (Educational Course). The 50<sup>th</sup> Annual Meeting of the American Society for Therapeutic Radiology and Oncology Meeting, 21-25 September 2008, Boston, U.S.A.
42. Advances in the management of nasopharyngeal cancer. The 8<sup>th</sup> Princess Margaret Hospital Conference Developments in Cancer Management: Conquering Cancer in our Lifetime, 16-18 October 2008, Toronto, Ontario, Canada.
43. Update on Chemoradiation for NPC. The 15<sup>th</sup> Hong Kong International Cancer Congress, 5<sup>th</sup> Annual Meeting of Centre for Cancer Research, 12-14 November 2008, Hong Kong.
44. Overview of collaborative trials in Hong Kong. First Hong Kong Australia Scientific Meeting of Head and Neck Oncology, 15 November 2008, Hong Kong.
45. Nasopharyngeal Cancer: Unique Opportunities (Gilbert H. Fletcher Distinguished Professor Lecture). The 4<sup>th</sup> International Conference on Translational Research and Pre-Clinical Strategies in Radiation Oncology, 11-13 March 2009, Geneva, Switzerland.
46. Overview of Clinical Trials in Nasopharyngeal Cancer. Asian Oncology Summit (AOS) 2009, 3-5 April 2009, Singapore.
47. Opportunities for Collaborative Researches on Nasopharyngeal Carcinoma. The 4<sup>th</sup> International Symposium on Nasopharyngeal Carcinoma, 18-20 June 2009, Marrakech, Morocco.
48. Nasopharyngeal Cancer – Unique Challenges. The 16<sup>th</sup> Hong Kong International Cancer Congress. 4-6 November 2009, Hong Kong.
49. Overview of Clinical Trials on Concurrent Chemoradiotherapy for Nasopharyngeal Cancer. The 4<sup>th</sup> World Congress of International Federation of Head and Neck Oncologic Societies, 15-19 June 2010, Seoul, Korea.
50. Management of Nasopharyngeal Cancer (Instructional Course). The 4<sup>th</sup> World Congress of International Federation of Head and Neck Oncologic Societies, 15-19 June 2010, Seoul, Korea.
51. Re-irradiation in Nasopharyngeal Cancer. The 29<sup>th</sup> Annual Meeting, European Society for Therapeutic Radiology and Oncology, 12-16 September 2010, Barcelona, Spain.

52. Management of Recurrent Nasopharyngeal Cancer – Challenges for All. The 5th International Symposium on Nasopharyngeal Carcinoma, 20-22 June 2011, Malaysia
53. Nasopharyngeal Cancer – How I Treat It (Instructional Course). The 3<sup>rd</sup> World Congress of the International Academy of Oral Oncology, 14-17 July 2011, Singapore.
54. Nasopharyngeal Cancer: Hong Kong Experience. The 2011 Academic Conference of TASTRO & 1<sup>st</sup> Annual Meeting of TAROS, 26-27 November 2011, Taiwan.
55. Battle against nasopharyngeal cancer (Award Lecture for Honorary Member of ESTRO). ESTRO 31, 9-13 May 2012, Barcelona, Spain.
56. Nasopharyngeal Cancer - Radiation Therapy: Current State. The 8th International Conference on Head and Neck Cancer, 20 – July 25, 2012, Toronto, Canada.
57. The Challenges of Constructing a National Staging Strategy: An Asian Perspective. The UICC World Cancer Congress, 27 – 30 August 2012, Montréal, Canada.
58. Impact of IMRT on Management of Nasopharyngeal Cancer. The 6th International Symposium on Nasopharyngeal Carcinoma, 20-22 June 2013, Istanbul, Turkey.
59. Contouring Course on IMRT for Nasopharyngeal Cancer. The 6th International Symposium on Nasopharyngeal Carcinoma, 20-22 June 2013, Istanbul, Turkey.
60. Role of induction chemotherapy in the nasopharyngeal carcinoma. 17<sup>th</sup> European Cancer Congress, 30 September - 1 October 2013, Amsterdam, Netherlands.
61. Nasopharyngeal Cancer - An Overview. The 24<sup>th</sup> Conference of the Scandinavian Society for Head and Neck Oncology, 20-21 April 2014, Stockholm, Sweden.
62. Treatment of Recurrent Nasopharyngeal Cancer. The 24<sup>th</sup> Conference of the Scandinavian Society for Head and Neck Oncology, 20-21 April 2014, Stockholm, Sweden.
63. Management of primary and recurrent nasopharyngeal cancer. The 5<sup>th</sup> World Congress of International Federation of Head and Neck Oncologic Societies & American Head and Neck Society, 26-30 July 2014, New York, U.S.A.
64. Technical Meeting on Genetic Characteristics and Response to Radiation Therapy of Nasopharyngeal Carcinoma in North Africa and China. International Atomic Energy Agency (Project No:325-E3-TM-47712), Vienna, 14-17 October, 2014.
65. Promoting TNM-Stage Use and Ensuring Stage is Globally Relevant. The 2014 World Cancer Congress, 3-6 December 2014, Melbourne, Australia.
66. Nasopharyngeal Cancer – Global Pattern & Lessons Learned from Hong Kong. Wharton Lecturer 2015. The 17th Annual Wharton / Elia Day Conference, 15 May 2015, Toronto, Canada.
67. Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome with Access to Radiotherapy. The 7<sup>th</sup> International Biannual Symposium on Nasopharyngeal Carcinoma, 4 – 6 June 2015, Yogyakarta, Indonesia.
68. Management of Nasopharyngeal Carcinoma. Multidisciplinary Teaching Course on “Management of Head & Neck Cancer,” by ESTRO School, 14-17 June 2015, Beijing, China.
69. Nasopharyngeal Carcinoma - Case Discussion. Multidisciplinary Teaching Course on “Management of Head & Neck Cancer,” by ESTRO School, 14-17 June 2015, Beijing, China.
70. Instructional Courses 1 - Nasopharynx Cancer Management 2016. The AHNS International Conference on Head and Neck Cancer, 16-20 July 2016; Seattle, USA.

71. Nasopharyngeal Cancer. The AHNS International Conference on Head and Neck Cancer, 16-20 Jul 2016; Seattle, USA.
72. The Fight against Cancer in Hong Kong & our Contribution to the Asia-Pacific Region. World Cancer Congress, 31 October- 3 November 2016, Paris, France.
73. Cancer classifications guiding patient care - China and GAG perspective on staging. World Cancer Congress, 31 October- 3 November 2016, Paris, France.
74. 10-Year Outcome on the Efficacy and Late Toxicities Attributed to the Addition of Concurrent-Adjuvant Chemotherapy for Stage III-IVB Nasopharyngeal Carcinoma (Combined Analyses of the NPC-9901 and NPC-9902 Trials). ASTRO 2017 Annual Meeting, 24-27 September 2017, San Diego, USA.
75. Landscape of Nasopharyngeal Carcinoma Current Management of Loco-Regional Disease. Head and Neck Steering Committee (HNSC) Nasopharyngeal Cancer (NPC) Clinical Trials Planning Meeting (CTPM), 27-28 January 2018, Phoenix, USA.
76. Evaluation of the global pattern of cancer survival and the correlation with healthcare expenditures. UICC, World Cancer Congress 2018, 30 September – 4 October 2018, Kuala Lumpur.
77. The Battle against Nasopharyngeal Cancer. The 1<sup>st</sup> International Conference of Nasopharyngeal Carcinoma 2018, University Sumatera Utara, 6-7 December 2018, Indonesia.
78. Emerging Radiotherapy Advances in Nasopharyngeal Cancer – What to Expect in the Next Decade? Nasopharyngeal Cancer Workshop 2019, The HEAD Foundation Singapore, 25-26 January 2019, Singapore.
79. IAEA Project (E33039): to Improve Outcome for NPC – Background & Design of Study. Second Research Coordination Meeting on Improving Radiotherapy Treatment Planning for Patients with Nasopharyngeal Carcinoma in Low- and Middle-Income Countries, the International Atomic Energy Agency (IAEA), 4-6 March 2019, Vienna, Austria.
80. IAEA Project (E33039): to Improve Outcome for NPC – Clinical Study on quality of Treatment Preliminary Data from 1st Phase (Baseline Assessment). Second Research Coordination Meeting on Improving Radiotherapy Treatment Planning for Patients with Nasopharyngeal Carcinoma in Low- and Middle-Income Countries, the International Atomic Energy Agency (IAEA), 4-6 March 2019, Vienna, Austria.
81. IAEA Project (E33039): to Improve Outcome for NPC – Recommendations on CTV Contouring, Dose Prioritization & Constraints. Second Research Coordination Meeting on Improving Radiotherapy Treatment Planning for Patients with Nasopharyngeal Carcinoma in Low- and Middle-Income Countries, the International Atomic Energy Agency (IAEA), 4-6 March 2019, Vienna, Austria.
82. IAEA Project (E33039): to Improve Outcome for NPC – Recommendations on Dose Fractionation & Imaging. Second Research Coordination Meeting on Improving Radiotherapy Treatment Planning for Patients with Nasopharyngeal Carcinoma in Low- and Middle-Income Countries, the International Atomic Energy Agency (IAEA), 4-6 March 2019, Vienna, Austria.
83. International Consensus of CTV Delineation. The 6th Asian Society of Head & Neck Oncology 2019, 27-30 March 2019, Seoul, South Korea.

84. The Strengths and Weaknesses of EBV-DNA as a biomarker for Nasopharyngeal Cancer. The 6th Asian Society of Head & Neck Oncology 2019, 27-30 March 2019, Seoul, South Korea.

### National Conferences

1. Altered fractionation for nasopharyngeal carcinoma. Seminar of continue education course on NPC radiotherapy, Department of Radiotherapy Cancer Centre, Sun Yat-Sen University, 9-10 November 2004, Guangzhou, China.
2. Advances in chemo-radiotherapy for nasopharyngeal carcinoma (Education Lecture). The 1st Pan-Pearl River Congress of Radiation Oncology, 12-14 May 2006, Guangzhou, China.
3. Multi-center Studies for Nasopharyngeal Cancer - Experience from Hong Kong Nasopharyngeal Cancer Study Group. The 3<sup>rd</sup> Pan-Pearl River Congress of Radiation Oncology, 23-24 Apr 2008, Fuzhou, China.
4. Quality Management System and External Accreditation for Clinical Oncology Department. The 4<sup>th</sup> Pan-Pearl-River Area Congress of Radiation Oncology, 23-26 April 2009, Wuhan, China.
5. Overview of Clinical Trials in Nasopharyngeal Cancer. The 5<sup>th</sup> National Conference on Nasopharyngeal Cancer, 31 July – 2 August 2009, Kunming, China.
6. Neoadjuvant Chemotherapy for Nasopharyngeal Cancer. The 6<sup>th</sup> National Conference on Nasopharyngeal Cancer, 11-12 December 2010, Fuzhou, China.
7. UICC TNM Staging – Overall Perspectives and Collaboration to Improve Cancer Staging. National Conference of Esophageal Cancer, 15-17 December 2011, Guangzhou, China.
8. Staging of Nasopharyngeal Cancer – Past, Present & Future. The 8th Pan-Pearl-River Area Congress of Radiation Oncology, 18-21 April 2013, Changsha, China.
9. Cancer Control in Hong Kong. The 9th Pan-Pearl-River Area Congress of Radiation Oncology, 17-20 April 2014, Chungqing, China.
10. Nasopharyngeal Cancer: Advances & Controversies in Chemoradiotherapy. The 7<sup>th</sup> Chinese National Nasopharyngeal Cancer Conference, 26-28 March 2015, Hangzhou, China.
11. Global Pattern on Nasopharyngeal Carcinoma – Correlation of Outcome with Access to Radiotherapy. The 10<sup>th</sup> Pan-Pearl-River Area Congress of Radiation Oncology, 16-19 April 2015, Guiyang, China.
12. Staging of Nasopharyngeal Carcinoma – Global Perspective. Chinese Society of Radiation Oncology, 30 October 2015, Chengdu, China.
13. Contribution by Hong Kong to the Battle against Nasopharyngeal Cancer. The 11th Pan-Pearl-River Area Conference of Radiation Oncology cum Prof. Ho Hung Chiu Memorial Symposium on Nasopharyngeal Cancer, 15-16 April, 2016; Shenzhen and Hong Kong, China.
14. Management of Nasopharyngeal Cancer – Evolving Technologies. The 13th National Conference on Radiation Oncology of CSTRO, 20-23 October, 2016, Chengdu, China.
15. 抗癌三部曲：战胜肿瘤不是梦。健康深圳大讲堂。2016年11月5日，中國深圳。



16. Nasopharyngeal Cancer: Evolution in the management of nasopharyngeal carcinoma -2016 and beyond. The 5th Guangzhou International Symposium on Oncology, 1-2 December, 2016, Guangzhou, China.
17. Long-Term Outcome for Concurrent-Adjuvant Chemotherapy for Advanced Nasopharyngeal Cancer. The 8th National Conference of Nasopharyngeal Cancer, 17-18 March, 2017, Shanghai, China.
18. Pursuit of Excellence for Management of Nasopharyngeal Carcinoma (NPC). 2017 Annual Meeting of Taiwan Head and Neck Society, 9-11 June 2017, Taipei, Taiwan.
19. Advances in Radiotherapy and Fundamental Standardization of Planning for Nasopharyngeal Cancer. The First International Particle Therapy and Clinical Research Summit (IPTCRS), 27-28 March 2018, Wuxi, China.
20. 鼻咽癌临床靶区(CTV)勾划国际指南要点解读, The 13th Pan-Pearl-River Area Congress of Radiation Oncology, 12-15 April 2018, Wuhan, Hubei, China.
21. The Applications and Limitations of EBV-DNA for Nasopharyngeal Cancer. Annual Conference on Radiation Oncology, Guangdong Medical Association, 12 July 2019, Guangzhou, China.

#### **Local Conferences**

1. Temporal lobe necrosis following radiation therapy for nasopharyngeal carcinoma. The 8<sup>th</sup> Asian Conference for Radiographers and Radiation Technologists, 10-13 October 1991, Hong Kong.
2. Nasopharyngeal carcinoma: survival after local recurrence. The 1<sup>st</sup> Scientific Meeting by Hong Kong Head and Neck Society, 4 March 1993, Hong Kong.
3. Nasopharyngeal carcinoma: local control by megavoltage irradiation. The 2<sup>nd</sup> Annual Scientific Meeting of Hong Kong College of Radiologists, 26 June 1994, Hong Kong.
4. Treatment of recurrent nasopharyngeal carcinoma – controversies and uncertainties. The Chinese University of Hong Kong, December 1998, Hong Kong.
5. Oncology services for orthopedic problems. Association of Private Orthopedic Surgeons, 22 June 2000, Hong Kong.
6. Induction chemotherapy with Cisplatin-Gemcitabine and concurrent accelerated chemo-RT for advanced nasopharyngeal carcinoma. Hong Kong Nasopharyngeal Cancer Study Group, 9 December 2003, Hong Kong.
7. Chemoradiation for NPC. The 12<sup>th</sup> Annual Scientific Meeting, Hong Kong College of Radiologists, 30-31 October 2004, Hong Kong.
8. Overview of Studies by the Hong Kong Nasopharyngeal Cancer Study Group. Hong Kong Head and Neck Society, 28 September 2006, Hong Kong.
9. Efficacy of Chemoradiation for Nasopharyngeal Carcinoma. Head and Neck Course 2007, Department of Surgery, The University of Hong Kong Medical Centre, 7 June 2007, Hong Kong.
10. Current Standard of Care for Different Stages of Nasopharyngeal Carcinoma. Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, 13 June 2007, Hong Kong.

11. Advances in the Management of Nasopharyngeal Cancer. Annual Scientific Symposium 2008, St. Teresa's Hospital Cancer Centre, 9 March 2008, Hong Kong.
12. Overview of Collaborative Trials in Hong Kong focusing on Nasopharyngeal Cancer. Hong Kong Head and Neck Society, 13 November 2008, Hong Kong.
13. Unique Challenges in the Battle against Nasopharyngeal Cancer. Hong Kong Medical Council, 15 September 2011, Hong Kong.
14. Nasopharyngeal cancer – Controversies about the best sequence for combining radiotherapy and chemotherapy. The 20<sup>th</sup> Annual Scientific Meeting, Hong Kong College of Radiologists, 27-28 October 2012, Hong Kong.
15. Nasopharyngeal Cancer: Controversy in Chemoradiotherapy. Hong Kong Nasopharyngeal Cancer Symposium, 23-24 August 2014, Hong Kong.
16. Contouring Course on IMRT for Nasopharyngeal Cancer. Hong Kong Nasopharyngeal Cancer Symposium, 23-24 August 2014, Hong Kong.
17. Clinical Trials of Head & Neck Cancer in Hong Kong – Past Achievements and Future Prospects. The Hong Kong Head & Neck Society, 15 October 2015, Hong Kong.
18. Nasopharyngeal Carcinoma. Gordon Research Conference, Hong Kong, 26 June – 1 July 2016.
19. Nasopharyngeal Cancer in Hong Kong over previous 60 years. The 3rd Hong Kong International Oncology Symposium, 28–30 October 2016, Hong Kong.
20. Pursuit of Excellence in Oncology Research-Progress in Therapeutics for Nasopharyngeal Carcinoma (NPC). ACRP Oncology Research Symposium, 1 April 2017, Hong Kong.